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  “ Ju mer man tänker desto mer inser man att det inte finns något enkelt svar”  
” The harder you think the more you realize there is no simple answer”  
  
Nalle Puh
  
ABSTRACT 
The menstrual cycle with fluctuation in female sex hormones has been suggested to influence 
neuromuscular function. However, variation in ligament laxity, soft tissue stiffness, and 
skeletal muscle strength across the menstrual cycle has led to conflicting results. 
Furthermore, premenstrual symptoms (PMS) have been suggested to have a negative impact 
on neuromuscular performance and contribute to the risk of musculoskeletal injury in 
physically active women. On the other hand, the use of oral contraceptives (OCs) might 
protect from injury. The mechanisms of the influence of sex hormones on neuromuscular 
function and PMS are not fully understood. 
The overall aim of this thesis was to explore the effect of endogenous sex hormones and OCs 
on muscle strength, postural control, and PMS in healthy women with moderate physical 
activity. A further aim was to explore the expression of sex hormone receptors in skeletal 
muscle during three well-defined phases of the menstrual cycle.   
Postural control was measured during the active and hormone-free phase of OC treatment in 
physically active women with or without PMS as evaluated by prospective symptom rating. 
In the same cohort of women, muscle strength and hop performance were measured during 
one OC cycle and one normal menstrual cycle at three specific phases, using a cross-over 
design. Furthermore, changes in PMS in the same women starting to use or discontinuing the 
use of OCs were evaluated. In another cohort of healthy women, muscle biopsies were 
collected from the musculus vastus lateralis in the follicular phase, the ovulatory phase, and 
the luteal phase of the menstrual cycle for determination of mRNA and protein levels of sex 
steroid hormone receptors. 
Women with PMS displayed a significant change in postural control (greater displacement 
area) during the active OC phase compared to the withdrawal phase of OC treatment, 
whereas women without such symptoms showed no variation in postural control during OC 
treatment. Muscle strength and hop performance did not vary during the different phases of 
the normal menstrual cycle, or during OC treatment. In women with PMS, OC treatment 
decreased ratings of premenstrual somatic symptoms, but not of negative mood symptoms. 
Gene and protein levels of estrogen receptor alpha and the progesterone receptor varied 
significantly during the three hormonally confirmed phases of the normal menstrual cycle. 
The results of this thesis indicate that PMS influences postural control and OC treatment 
decreases PMS of somatic type. Furthermore, muscle strength and hop performance are not 
influenced by endogenous and exogenous sex hormones. The variation in expression of sex 
hormone receptors in skeletal muscle may have an impact on the effects of muscular training 
and sports injuries in women. 
Key words: postural control, balance, muscle strength, estrogen, progesterone, hormone 
receptor, oral contraceptives. 
  
SAMMANFATTNING 
Kvinnor har en ökad skaderisk för muskuloskeletala skador inom idrott i jämförelse med 
män. Menstruationscykeln med variation av könshormoner har föreslagits kunna påverka 
neuromuskulär funktion. Dock har studier visat varierande resultat när laxitet i ligament, 
muskulär stelhet och muskelstyrka har relaterats till olika faser i menstruationscykeln. Vidare 
förefaller förekomst av premenstruella symtom (PMS) kunna bidra till högre skadefrekvens 
genom påverkan på balans och neuromuskulär funktion. Däremot kan p-piller möjligen 
minska risken för muskuloskeletala skador hos aktiva kvinnor. Mekanismerna för hur 
könshormoner påverkar neuromuskulär funktion och PMS är inte helt kartlagda.  
Syftet med föreliggande avhandling var att undersöka effekten av kroppsegna könshormoner, 
p-piller samt PMS på balans, muskelstyrka och hoppfunktion. Ett annat syfte var att studera 
uttrycket av hormonreceptorer i muskelvävnad vid tre väldefinierade faser under 
menstruationscykeln.  
Balans mättes i enbensstående på en kraftplatta under den aktiva samt den hormonfria fasen 
vid p-pillerbehandling hos fysiskt aktiva kvinnor med och utan PMS. Detta utfördes med 
prospektiv daglig självskattning av symtom. I samma studiekohort mättes muskelstyrka och 
hoppfunktion under en p-pillercykel samt vid tre specifika faser i en menstruationscykel med 
crossover design. Dessutom undersöktes förändringar av PMS hos kvinnor som började 
använda eller slutade använda p-piller. I en annan studiekohort av friska kvinnor togs 
muskelbiopsier från lårmuskulaturen i follikelfas, ovulationsfas samt lutealfas under 
menstruationscykeln för att analysera mRNA- och proteinnivåer av könshormonreceptorer.  
Kvinnor med PMS uppvisade signifikanta förändringar i balans under den aktiva p-
pillerfasen i jämförelse med uppehållsfasen. Dessa förändringar sågs inte hos kvinnor utan 
PMS under p-pillermedicinering. För muskelstyrka och hoppfunktion påvisades ingen 
variation under olika faser i menstruationscykeln eller under p-pillermedicinering. För 
kvinnor med PMS, visade sig p-piller signifikant kunna minska fysiska symtom, såsom 
bröstspänning och svullnad, men inte negativa psykologiska symtom, såsom irritabilitet och 
nedstämdhet. Genuttryck och proteinnivåer av östrogen receptor alpha och progesteron 
receptorn visade sig variera signifikant under tre hormonellt verifierade faser av 
menstruationscykeln.  
 Resultatet av denna avhandling visar att PMS påverkar balans och att p-pillermedicinering 
kan ge minskade fysiska symptom. Dessutom visades att muskelstyrka och hoppfunktion inte 
påverkas av vare sig av kroppsegna hormoner eller syntetiska hormoner i p-piller. Hypotetiskt 
kan variationen i uttrycket av könshormonreceptorer i skelettmuskulatur påverka muskulär 
träning och risken för idrottsskador hos kvinnor under olika faser av menstruationscykeln.  
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LIST OF DEFINITIONS  
In the present thesis, the following abbreviations were used to define a certain feature.  
CD scale  
 
Cyclic   
 
 
Cycle…………………… 
 
Endogenous sex 
hormones  
Exogenous sex  
hormones  
 
Muscle torque  
Non-OC phase  
Non OC-Starters 
 
Non-OC user  
OC user  
OC phase  
OC-Starters 
 
Sex hormones 
 
 
 
Assessment tool used for rating of premenstrual 
symptoms 
A cyclic increase in premenstrual symptoms during the 
luteal phase compared to the follicular phase of the 
menstrual cycle 
The entire menstrual cycle from menses to menses, in 
both a normal menstrual cycle or during oral 
contraceptive cycle 
 
The natural sex hormones in females (estradiol, 
progesterone, testosterone). 
The synthetic hormones in oral contraceptives 
 
A force that produce a rotation or torsion 
The withdrawal phase of the oral contraceptive cycle 
The women who were enrolled having a normal 
menstrual cycle (not using oral contraceptives) 
A woman having a normal menstrual cycle  
A woman during oral contraceptive use 
The active hormone phase of the oral contraceptive cycle  
The women who were enrolled and were taking oral 
contraceptives. 
Umbrella term used in this thesis to describe the 
endogenous sex steroid hormones (estradiol, 
progesterone, testosterone) and the synthetic hormones in 
oral contraceptives (ethinyl estradiol and progestagens) 
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1 INTRODUCTION 
The benefits of regular physical activity for somatic and mental health are remarkable for 
humans of all ages. The number of women taking part in sports at all levels is steadily 
increasing; for example, there are races devoted to women only, such as “Tjejmilen,” 
“Tjejvasan,” and “Tjejvättern.” Also in team sports, there is a growing number of female 
participants. Disquietingly, women seem to be more vulnerable to sustaining traumatic 
injuries during jumping and cutting sports (Arendt et al., 1999: Boden et al., 2000; Huston et 
al., 2000 review; Myklebust et al., 1997; Åman et al., 2016) and they also have a higher rate 
of overuse injuries compared to their male counterparts (Brukner & Bennel, 1997; Ross et al., 
2015; Schroeder et al., 2015). Besides, it has been shown that these injuries occur earlier in 
life in females (Myklebust et al., 1998; Schroeder et al., 2015).  
There are obvious anatomical and physiological differences between the mature female and 
male that explain the mean difference in physical performance between the sexes 
(Drinkwater, 2008). However, the most basic feature in women is the menstrual cycle with 
the fluctuation in sex hormones throughout the month. The sex hormones involved in the 
menstrual cycle are estradiol (E2), progesterone (P-4), testosterone (T), follicle-stimulating 
hormone (FSH), and lutenizing hormone (LH). Some of these hormones have been suggested 
to play a role in the etiology of musculoskeletal injuries in women. Additionally, the presence 
of premenstrual symptoms (PMS), such as breast tenderness, depressed mood, and irritability, 
has also been suggested to be a risk factor for injuries in women (Möller-Nilsen & Hammar, 
1989). PMS of variable severity are common in fertile-aged women. Despite the well-known 
symptoms, the etiology of PMS has still not been fully elucidated. PMS seems to be caused 
by mechanisms in the central nervous system (CNS) and has been shown to alter postural 
control in women (Fridén et al., 2003b; 2005).  
As a physiotherapist, working at a clinic specialized in sports medicine, I meet females with 
traumatic and overuse injuries. They describe how debilitating the injury is and how it 
interferes with their work and social and physical activities. Besides, it is also known that 
there might be increased risks of developing osteoarthrosis after having a serious traumatic 
injury: for example, rupture of the anterior cruciate ligament (ACL) in the knee. To gain a 
better understanding of the mechanisms of musculoskeletal injuries in women, it is important 
to find out more about the hormonal effects, both endogenous and exogenous, as in the case 
of oral contraceptives (OCs), and the eventual effects of PMS on physical performance.  
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This thesis is focused on studies aimed at evaluating postural control, muscle strength, and 
hop performance in relation to OC use and PMS in physically active women. In addition, we 
characterized the expression of sex steroid hormone receptors during the menstrual cycle. The 
main concepts of this thesis are illustrated in Fig. 1.  
 
 
Fig. 1. The main concepts of the present thesis. 
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2 BACKGROUND 
2.1 THE SKELETAL MUSCLE  
2.1.1 Skeletal muscle physiology 
The skeletal muscle system is one of the largest systems in the body. Skeletal muscles act on 
the skeleton via voluntary control through the CNS (Watras, 2008). There are several 
functions of the skeletal muscles: maintenance of posture, locomotion, and respiration. The 
basic structure of the skeletal muscle is shown in Fig. 2. The skeletal muscle comprises 
numerous elongated cells called muscle fibers, which are grouped together into fascicles that, 
together, form the muscle. Connective tissue surrounds each muscle fiber (endomysium), 
each fascicle (perimysium), and the entire muscle (epimysium). At the end of the muscle, the 
connective tissue layers emanate together to form a tendon that attaches the muscle to the 
skeleton (Watras, 2008).  
 
 
 
 
Fig. 2. Structure of the skeletal muscle.           
Adapted from https://upload.wikimedia.org/wikipedia/commons/e/ef/Skeletal_muscle_diagram.jpg 
 
Muscle fibers are supplied by α- and γ-motor neurons which, together with muscle fibers, 
form the motor unit. The size of the motor unit depends on how precise a control of the 
muscle is required. For example, in the finger muscles, a single α-motor neuron supplies only 
a few muscle fibers, compared to the muscle in the thigh, where a single α-motor neuron can 
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supply numerous muscle fibers. The motor unit is the functional contractile unit since all the 
muscle fibers within the motor unit contract synchronously when the motor nerve fires 
(Rubinson & Lang, 2008). Contracting muscles require large quantities of energy. Depending 
on the duration and intensity of the work, as well as the availability of oxygen to meet the 
demands of the working muscle, there are three integrated systems of metabolism in the 
muscle fibre: aerobic metabolism (e.g., during endurance exercises), anaerobic metabolism 
(e.g., during high power output), and alactacid breakdown of adenosine triphosphate (ATP)  
(Gastin, 2001 review). It should be mentioned that these systems interact in the muscle in 
various proportions (Gastin, 2001 review).  
The muscular system comprises over 40% of the body’s mass in males and about 23% of the 
body’s mass in females (Cureton, 1998). This explains the mean difference in muscle 
strength between the sexes. The difference in muscle mass and strength is greater in the upper 
body, compared to the lower limbs (Hewett, 2000 review).  
 
2.2 POSTURAL CONTROL 
2.2.1 Postural control – definition 
Postural control is used synonymously with postural balance and is defined as the ability to 
achieve a state of equilibrium by controlling the body’s center of mass (CoM) in relation to 
the body´s base of support (BoS) in standing, as well as during complex motor tasks (Horak 
& Macpherson, 1996; Lephart & Fu, 2000). The functional goal of postural control is to 
maintain postural equilibrium and postural orientation (Horak, 2006). Postural control is 
complex and is influenced by several bodily systems, such as the sensory, neuromuscular and 
cognitive systems within the CNS and the peripheral nervous system (PNS). It includes 
systems involved in higher-level planning (frontal cortex and motor cortex in the forebrain), 
coordination (in the brainstem and spinal networks coordinating muscle response synergies), 
and generation of forces (in the motor neurons and the muscle) which produce effective 
movements to control the body’s posture in space (Shumway-Cook & Woollacott, 2012).  
 
2.2.1.1 Neuromuscular control  
Neuromuscular control is the dynamic input that assists in the maintenance of equilibrium 
via afferent information and efferent motor response (Riemann & Lephart, 2002).  The 
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control of balance involves continuous feedback and feed-forward in processing visual, 
vestibular, and somatosensory inputs and executing neuromuscular actions (Shumway-
Cook & Woollacott, 2012). The somatosensory system consists of specifically designed 
peripheral receptors that exist in the muscles (the muscle spindle), tendons (Golgi tendon 
organ) and the joints, and in the skin. These receptors detect changes in the specific 
structure, such as stretch and pressure and send afferent information about changes in body 
position to higher centers within the CNS (Riemann & Lephart, 2002; Shumway-Cook & 
Woollacott, 2012). This information is processed in the CNS and efferent information is 
sent out via α-motor neurons to the muscles in action (Fig. 3). The feed-forward control is 
an anticipatory strategy used to prevent disturbance of the CoM with small, unconscious 
body movement before and during voluntary movements (Shumway-Cook & Woollacott, 
2012).  
 
Fig. 3. Illustration of the systems involved in neuromuscular control. 
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2.2.2 Postural control – evaluation 
Stabilometry or kinetic analyses are techniques used to evaluate the forces that contribute to 
movement or stability. It can be assessed by using a force platform that measures ground 
reaction forces (GRFs), which are the forces exerted by the ground on the body in contact 
with it. The resultant force of all the GRFs emanates to the point of attack and this is the 
center of pressure (CoP) (Winter, 1995;1998). Quiet stance is characterized by small 
amounts of spontaneous postural sway that contribute to postural stability in this situation 
(Shumway-Cook & Woollacott, 2012; Winter, 1998). The size and shape of the BoS can be 
varied, e.g., due to two-legged stance, one-legged stance, and tandem stance in different 
settings.  
Dynamic postural control and neuromuscular movement patterns can be evaluated by 
kinematic analyses. Kinematics measures motion independent of the causative forces by 
tracking body segments during movement tasks (Winter, 1995) There are different 
techniques in the laboratory setting to measure the body’s movement in space: for example, 
by a three-dimensional optoelectronic system (Wikström et al., 2004; Winter, 1995).  
In clinical settings, several validated measurement tools and test batteries have been 
developed to evaluate balance and postural control in specific patient groups with altered 
postural control (e.g., neurological diseases) (Horak et al., 2009) and for sports medicine 
purposes (Wikström et al., 2006). The assessment of postural control has several 
implications for identifying subjects with an elevated risk of musculoskeletal injuries and 
evaluating the effects of rehabilitation programs (Rogind et al., 2003).  
 
2.2.3 Neuromuscular aspects of musculoskeletal injuries in females  
Females have a three- to six-fold higher incidence of sustaining an ACL injury in sports than 
males. Evidence in the literature suggest poor neuromuscular control in the biomechanics of 
the lower limb, and in particular the knee joint during the execution of potential hazardous 
sporting movements, is a primary contributor to the female ACL injury mechanism (Hewett, 
2000 review; Hewett et al., 2005; McLean et al., 2004, Renström et al., 2008 review). 
Differences between females and males in neuromuscular recruitment patterns and forces of 
landing have been proposed to explain the discrepancy. Females have been suggested to be 
dominant in their quadriceps muscle with response to an anterior tibial translation and 
extension of the knee, during landing from a jump (Hewett et al. 2006; Renström et al., 2008 
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review). The knee extensor muscles are antagonists to the ACL and increase strain on the 
ACL in knee flexion angles below 45°. In contrast, males are more hamstrings dominant and, 
by landing in a knee flexion pattern, the recruitment of hamstring muscle contributes to 
stabilization of the knee as a dynamic agonist to the ACL (Hewett, 2000 review; Renström et 
al., 2008 review). Further, females have shown differences in hip muscle activity with a 
greater femoral internal rotation and hip adduction that place the knee in a valgus position 
(Zeller et al., 2003).  
Disturbance in postural control and neuromuscular function seems to be a cornerstone for 
understanding the elevated risk of musculoskeletal injuries in women. In the present thesis, 
postural control was evaluated in quiet standing in relation to hormonal variation during the 
use of OC, as well as the influence of PMS (Paper I).  
 
2.3 THE MENSTRUAL CYCLE 
An average menstrual cycle lasts for 28 days in regularly menstruating women. The 
menstrual cycle involves the interaction of several endocrine glands and a responsive uterus 
which are controlled by a feedback system in the hypothalamus–pituitary–gonadal axis (Fig. 
4).  The most important hormones that control the menstrual cycle are gonadotropin-releasing 
hormone (GnRH), produced in the hypothalamus, FSH and LH released from the anterior 
pituitary, and E2 and P-4 from the ovaries (Beshay & Carr, 2013; Drinkwater, 2008;). 
 
Fig. 4. The hypothalamus–pituitary–gonadal axis feed-back system for production of sex 
hormones. Adapted with the kind permission of CCC Rights Link® (Popat, Prodanov, Calis & Nelson, 2008). 
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The menstrual cycle can be divided into three hormonally different phases: the follicular 
phase, the ovulatory phase, and the luteal phase (Fig. 5). The follicular phase starts with the 
first day of menstrual bleeding (cycle day 1). During the follicular phase, FSH from the 
pituitary stimulates the maturation of antral follicles in the ovaries. After about one week, a 
selection of a predominant follicle occurs. When this follicle grows, the level of E2 steadily 
increases to reach the highest levels just before ovulation. At the peak of the follicular 
growth, ovulation takes place, with a rapid increase of LH (the LH surge) from the pituitary. 
LH is released as a result of a positive feedback action from high circulation levels of E2 on 
the anterior pituitary.  An oocyte is released about 12 h after the LH surge and, with this 
action, the levels of E2 decline for a few days. The secretion of androgens such as 
androstendione and T from the ovary is stimulated by LH and the androgen level peaks 
simultaneously with the LH surge. The action of the androgens at this point is to enhance 
atresia of non-dominant follicles and to stimulate libido (Beshay & Carr, 2013; Fritz & 
Speroff, 2011). During the luteal phase, the ruptured follicle is formed into the corpus luteum, 
which secretes both E2 and P-4. One week after ovulation, during the mid-luteal phase, the 
levels of P-4 peak together with a secondary rise of the E2 levels. In the case of non-
fertilization, the corpus luteum will gradually degenerate and the production of sex hormones 
will decline. The withdrawal of E2 and P-4 causes a degradation of the endometrium and next 
menstruation starts (Drinkwater, 2008).  
Although the median duration of a menstrual cycle is 28 days, the normal range can vary 
between 25–30 days (Beshay & Carr, 2013). The luteal phase is about 14 days in most 
regularly menstruating women, but the follicular phase can vary more in length. The 
biological variety in cycle length between individuals and the fact that spontaneous 
anovulatory cycles are common causes methodological problems in menstrual cycle-related 
studies (Metcalf et al., 1980). In these kinds of studies, it is therefore necessary to determine 
different cycle phases with hormone analyses or a gynaecological evaluation (Sarwar et al., 
1996). Since several factors such as diurnal variation, stress, and physical activity might 
affect the hormone levels, a standardized protocol for blood sampling is a prerequisite 
(Constantini et al., 2005; Vescovi, 2011).  
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Fig. 5. A normal menstrual cycle lasts in most regularly menstruating women for 28 days and 
can be divided into the follicular phase, the ovulation phase, and the luteal phase.               
The menstrual cycle: http://commons.wikimedia.org/wiki/File:MenstrualCycle.png by Chris73 (Licens Creative 
Commons BY NC SA) 
 
2.4 SEX HORMONES 
The sex hormones belong to a group of structurally related hormones, steroid hormones that 
are synthesized from cholesterol. Steroid hormones are lipophilic and can readily cross both 
the cell membrane and the nucleus membrane (Lackie, 2015). The biological effects of sex 
steroids can be displayed through genomic mechanisms by ligand binding to intracellular 
nuclear receptors or, more rapidly, by a non-genomic mechanism through membrane-bound 
receptors (Fig. 6) (McEwen, 2012 review; Sakamoto et al., 2012). After the ligand binding, 
the regulation of gene expression and production of proteins is initiated (McEwen, 2002).  
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Fig. 6. Simplified illustration of the mechanism of signalling pathways for steroids:     
Pathway 1, genomic binding (classical, transcriptional), the steroid (S) binds to an 
intranuclear receptor the receptor dimerize and binds to the genome and activates the 
hormone responsive element (HRE), leading to transcription of messenger ribonucleic acid 
(mRNA) and protein synthesis. Pathway 2, non-genomic binding, the steroid (S) binds to a 
membrane-bound receptor for rapid signalling via flux of ions through the membrane or 
second-messenger (SM) signalling usually changing the membrane potential making it 
easier or more difficult for action potential generation.  
 
2.4.1 Estrogen  
Three types of estrogens are present in the human body: the most dominant and potent 
estrogen is E2, which is produced by the granulosa cells in the ovary. Additionally, E2 can be 
produced by aromatization from androgens in other tissues like brain, fat, and in the liver 
(Brodie & Inkster, 1993; Miller, 1991) (Fig. 7). The other less potent estrogens, estrone (E1) 
and estriol (E3) are produced from E2 by conversion in peripheral tissues. Most of the 
estrogens are bound to carrier proteins and are transported to the target tissues. Albumin 
carries 60% of the estrogens and 38% is carried by sex hormone-binding globulin (SHBG). 
The remaining 2% is free in the blood circulation and this fraction can enter the cells in the 
human body and bind to its specific receptor. There are two known nuclear estrogen receptors 
(ERs) in the human body, ERα and ERβ. The functions of estrogens are varied with actions 
on the reproductive system, the nervous system (Joels, 1997; McEwen, 2012 review), the 
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skeletal system (Fritz &Spearoff, 2011) the immune system (Carlsten et al., 1989), and the 
muscular system (Wiik et al., 2003; 2005). 
 
 
Fig. 7. Illustration of steroid hormone synthesis. 
 
2.4.1.1 Estrogen effects on skeletal muscles 
Receptors for estrogens, both the ERα and the ERβ, have been demonstrated in human 
skeletal muscle cells (Lemoine et al., 2003; Wiik et al,. 2003; 2009). Furthermore, receptors 
for estrogens have been detected in human ACL (Lie et al., 1997; Liu et al., 1996; Yu et al., 
1999). Wiik et al., (2005) have shown that ERs´ in the skeletal muscle are up regulated in 
response to endurance training in men. The effects of estrogen on human skeletal muscle 
function have not, however, been fully elucidated. Animal studies support the view that 
estrogen has anabolic properties, including contractile function, as well as playing an 
important role in stimulating muscle repair and regenerative processes with an enhanced 
activation of silent satellite cells (Enns & Tiidus, 2010 review; Skelton et al., 1999). In 
humans, studies on the acute effects of high levels of estrogen on muscle strength during the 
menstrual cycle have shown contradictory results. Phillips et al., (1996) and Sarwar et al., 
(1996) have demonstrated an increased maximal voluntary isometric muscle force during 
ovulation (cycle days 12–18) in healthy women, when the levels of E2 are at the highest. 
Other authors have not been able to show any differences in muscle strength during the 
menstrual cycle in healthy fertile-aged women (Fridén et al., 2003; Gür, 1997; Gür et al., 
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1999; Janse de Jonge et al., 2001; Lebrun et al. 1995; Montgomery & Shultz, 2010). In two 
recent studies on postmenopausal women, estrogen replacement therapies demonstrated 
positive effects on reduction of the age-related decline in muscle strength (Dieli - Conwright 
et al., 2009; Ronkainen et al., 2009). However, other studies have not been able to show any 
effects of estrogen supplement on muscle strength in menopausal women (Enns & Tiidus, 
2010 review).  
Estrogen has also been suggested to affect muscular stiffness and ligament laxity in normally 
menstruating women. Eiling et al., (2007) found a significantly lower active stiffness in the 
muscle of the lower extremities during ovulation (high E2), compared to the early follicular 
phase (low E2). Similar, a negative relationship between estrogen and muscle stiffness was 
shown by Bell et al., (2012). Hansen et al., (2013) did not, however, find differences in soft 
tissue stiffness in relation to menstrual cycle phases in female athletes. Some authors have 
demonstrated an increase in ligament laxity in relation to specific phases of the menstrual 
cycle when estrogen levels are high (Deie et al., 2002; Heitz et al., 1999; Shultz et al., 2004). 
These findings and conclusions have been refuted by other reports (Arnold et al., 2002; 
Bennon et al., 2002; Karageanes et al., 2000). Beynnon et al., (2005) concludes the ligament 
laxity to be grater in women compared to men, however, the menstrual cycle with fluctuation 
in E2 and P-4 was reported not to affect the ligament laxity.  
Periodized high intense resistance training in women during the follicular phase (totally high 
levels of E2) has been shown to increase leg muscle strength in untrained to moderately 
trained women (Reis et al., 1995; Sung et al., 2014). These results were more recently 
confirmed by Wikström-Frisén et al., (2015). They showed improved performance in squats, 
countermovement jumps and peak torque for hamstring muscles after periodized resistance 
training with more frequent training during the follicular phase. Furthermore, an increase in 
lean body mass was also observed (Wikström-Frisén et al., 2015). However, in the above 
study, both women with a regular normal menstrual cycle and women on different types of 
oral contraceptives were mixed. 
 
2.4.2 Progesterone 
Progesterone, secreted from the corpus luteum, is mainly bound to albumin in the circulation 
and only a few percent is free and could easily enter the cells and bind to its specific receptor 
(Fritz & Speroff, 2011). There are two main isoforms of the classical nuclear receptors for 
progesterone, the progesterone receptor A (PR-A) and the progesterone receptor B (PR-B) 
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(Conneely & Lydon, 2000). Progesterone is a key hormone for conception and pregnancy 
maintenance (Fritz & Speroff, 2011).  
 
2.4.2.1 Progesterone effects on skeletal muscles 
Very little is known about the physiological effects of progesterone on human skeletal 
muscle. Copas et al., (2001) have demonstrated PR in the skeletal muscle of the pelvic floor 
in postmenopausal women. In a recent review by Oosthuyse & Bosch, (2010), circulating P-4 
was suggested to correlate with an increased protein catabolism due to a greater oxidation of 
amino acids in the luteal phase.   
 
2.4.3 Androgens 
The term androgen is used to describe all male sex hormones. Testosterone and 
dihydrotestosterone are both synthesized from androstenedione (Fig. 7). Testosterone is 
considered to act as an anabolic hormone by increasing protein synthesis and decreasing 
protein degradation (Crewther et al., 2011 review). There is one known nuclear receptor for 
androgens in central and peripheral tissue, the androgen receptor (AR).  
 
2.4.3.1 Androgen effects on skeletal muscles 
Increased protein metabolism, muscle growth, and improvement in physical performance 
with the influence of exogenous testosterone in combination with training are well 
documented in men (Crewther et al., 2011 review; Hartgens & Kuipers, 2004 review).  
Receptors for androgens have previously been found in human male skeletal muscle. Kadi 
et al., (2000) found that the distribution of AR per fiber cross-section differs between 
muscles types. A higher distribution was demonstrated in the upper body (back and chest), 
compared to in the lower limbs, in male subjects (Kadi et al., 2000). The proportion of AR 
per fiber cross-section area was significantly higher in power lifters than in untrained 
controls, but only in the upper body. For the group of power lifters using exogenous 
androgen steroids, this up-regulation in AR was significantly elevated over those not using 
drugs, and still only in muscles of the upper body (Kadi et al., 2000). In the case of females, 
AR has previously only been demonstrated in skeletal muscles of the pelvic floor of 
postmenopausal women. The muscular function of the AR was, however, not investigated 
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in this study (Copas et al., 2001). Less is known about the occurrence and effects of 
androgens on muscle performance in fertile-aged women. However, female athletes with 
polycystic ovary syndrome (PCOS) were shown to have higher maximal oxygen uptake 
(VO2max) and the highest performance values compared to non-PCOS athletes (Constantini, 
1995; Rickenlund et al., 2003).  
The demonstration of hormone receptors in human muscle tissue is quite new. There are 
few studies on hormone receptors in female muscle tissue, but no available research has 
evaluated the variation of sex hormone receptors during the menstrual cycle in fertile-aged 
women. In the present thesis, the aim of Paper IV was to explore the representation of 
hormone receptors in skeletal muscles during three specific phases of the menstrual cycle.  
 
2.4.4 Neurosteroids 
The sex hormones, E2, P-4, T, and their potent metabolites, are synthesized and released in 
the central and peripheral nervous system and can therefore be classified as neurosteroids 
(Compagnone & Mellon, 2000; McEwen, 2012 review). These sex steroid hormones may act 
directly by binding to their specific receptors, but can also exhibit modulatory effects on the 
synaptic transmission involved in emotional and cognitive control: for example, the 
noradrenergic, the dopaminergic, the serotoninergic and the γ-aminobutyric acid (GABA)-
ergic systems (Toffoletto et al., 2014 review). Allopregnanolone, a metabolite of 
progesterone, increases during the luteal phase and is considered to be of importance for PMS 
by influencing the GABA and the serotonin system (Sundström, 1999). 
 
2.5 PREMENSTRUAL  SYMPTOMS 
2.5.1 Prevalence and diagnostics 
More than 75% of women of fertile age experience one or more symptoms of PMS. The 
symptoms are characterized by negative mood and/or somatic disturbance during the luteal 
phase (Angst et al., 2001). The severity of the symptoms gradually increases during the late 
luteal phase and usually peaks about two days before the menses and subsides a few days 
after the onset of menses (Bäckström et al., 1983; Pearlstein et al., 2005). The symptoms are 
mild in most women and cause no impairment in daily activity and could be considered 
physiological rather than pathological. However, about 20% of fertile-aged women have 
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premenstrual complaints of clinical relevance (Yonkers et al., 2008 review) and about 3–8% 
have symptoms that are severe and associated with substantial distress and functional 
impairment that markedly affect the activity of daily living and require medical management 
(Sveindottir & Bäckström, 2000). The most frequently reported somatic symptoms are breast 
tenderness and bloating and the most common mood symptoms are irritability, depressed 
mood, and fatigue.  
The former disagreement about terminology and diagnostic criteria led to a consensus report 
on the severe form of PMS. The proposed criterion was adopted by the American Psychiatric 
Association’s Diagnostic and Statistical Manual V (DSM-5). The disorder was entitled 
premenstrual dysphoric disorder (PMDD) (APA, 2013). The diagnosis of PMDD (3–8 % of 
fertile-aged women) requires at least five luteal phase disorders, whereof at least one must be 
a negative mood symptom (e.g., irritability, depressed mood, fatigue, tension). The timing of 
the symptoms must be recorded by daily prospective ratings during at least two cycles and the 
symptoms should be severe enough to cause functional impairment. Additionally, the 
symptoms should not be an exacerbation of another psychiatric disorder. To differentiate 
PMS/PMDD from other psychological issues, the symptom-free interval before ovulation is 
crucial in the diagnostics of PMS (Bloch et al., 1997; Hammarbäck et al., 1989). PMS is not a 
laboratory-directed diagnose, since levels of hormones are often equal in women with and 
without PMS/PMDD (Rubinow & Schmidt, 1995).  
 
2.5.2 Etiology and pathophysiology 
It is still a challenge to understand the etiology and pathophysiology of PMS, but advances 
have been made in recent years. Since mood and behavioural symptoms are key features of 
PMS, the underlying mechanism should involve the brain and neurotransmitters within the 
brain (Yonkers et al., 2008 review). Theories suggest symptoms to be triggered by the 
postovulatory peak in progesterone with the metabolites of progesterone acting in the brain 
(Schmidt et al., 1998; Nevatte et al., 2013; Ismaeli et al., 2016). Since the symptoms 
disappear during anovulatory cycles, the formation of corpus luteum is necessary for the 
development of PMS (Hammarbäck et al., 1988; 1991). The increased levels of progesterone 
metabolites acting on the inhibitory transmitter systems in the brain seem to be important for 
the development of PMS in women (Bäckström et al., 2011). Since there are no differences in 
serum levels of sex hormones in women with and without PMS (Rubinow & Schmidt, 1995), 
there are indications that some women are more sensitive to the normal fluctuation of sex 
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hormones and especially to the neuroactive metabolites allopregnanolone (3α-OH-5α-
pregnan-20-one) and pregnanolone (3α-OH-5β–pregnan-20-one) (Rapkin et al., 1997). 
Gamma-butyric acid and its A-receptor (GABA-A) constitute the most important inhibitory 
system in the brain and the site of action for benzodiazepines, barbiturates, and ethanol, as 
well as for endogenous neuroactive steroids (Sundström et al., 1999). Allopregnanolone and 
pregnanolone exert a rapid, non-genomic inhibitory effect on excitability neurons that 
directly modulate the activity of the GABA-A receptor (Biggo et al., 2001). Normally, 
positive modulation of the GABA-A receptor gives rise to anxiolytic and calming effects. 
However, in some individuals, particularly women with severe PMS, the effects of the 
modulation are the opposite and cause irritability and anxiety. This reaction is called a 
paradoxical reaction where low doses of allopregnanolone cause a negative mood and high 
doses a calm mood (Bäckström et al., 2014 review).  
Estrogen metabolites are also neurotransmitters with an action in the nervous system that 
regulates and controls, e.g., fine motor function, coordination, pain, mood, cognitive function, 
and neuroprotection (McEwen, 2012 review).  
It is unclear whether somatic symptoms of PMS are caused by changes in hormone-
responsive peripheral tissue or if they might be a result of reduced tolerance of physical 
discomfort while in a dysphoric mood state. Studies on premenstrual-related fluid retention, 
breast enlargement, and weight gain have failed to show such a relation (Yonkers et al. 2008 
review). It should be mentioned that menstrual-related headache and dysmenorrhoea are not 
somatic premenstrual symptoms, but separate conditions (Yonkers et al., 2008 review).  
 
2.5.3 Therapeutic management of PMS 
2.5.3.1 Medical treatment with selective serotonin re-uptake inhibitors, GnRH 
analogues, and OCs 
The most common medical treatments for PMS and PMDD are aimed at influencing the 
neurotransmitters in the brain, such as the selective serotonin re-uptake inhibitors (SSRIs) 
(Nevatte et al., 2013). In a meta-analysis, Dimmock et al., (2000) considered SSRIs to be 
effective first-line therapy for severe PMS. SSRIs affect the serotonergic transmitter system 
without affecting ovarian steroid production. Ovulation persists as normal with this treatment. 
Frequently reported side effects of SSRI treatment are decreased libido, insomnia, fatigue, 
and nausea (Dimmock et al., 2000).  
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Since PMS does not occur in anovulatory cycles, treatments that supress ovulation are 
particularly interesting (Wyatt et al., 2004 review). GnRH analogues downregulate the GnRH 
receptors and, by this action, inhibit ovulation. In a meta-analysis of seven randomized 
controlled trials, GnRH has shown high efficacy in the treatment of PMS/PMDD (Wyatt et 
al., 2004 review). There is, however, a risk of a low estrogenic state due to the inhibited 
ovulation. Add-back therapy of E2 and progesterone has been shown not to reduce the 
treatment effects of GnRH (Segebladh et al., 2009).  
Oral contraceptives (see part 2.6 later in this thesis) have been show to improve somatic 
symptoms (Bäckström et al., 1992). Concerning mood disorders, there are still contradictory 
results and the effect seems to depend on the type of progestagen and the treatment regimen, 
where continued use or shortening the withdrawal phase has been shown to improve mood 
symptoms, at least in women with mild symptoms (Nevatte et al., 2013). Mood disorders are, 
however, the major reason for discontinuation of OC treatment (Larsson et al., 1997). A 
novel OC containing the progestagen, drospirenone, which is derived from spironolactone 
instead of testosterone, has been demonstrated in studies to have properties that influence 
fluid balance (Kurshan et al., 2006; Pearlstein et al., 2005; Yonkers et al., 2005). In a 
Cochrane report, drospirenone has been considered to be treatment for PMS and PMDD, with 
improvement in both somatic and mood-related disorders (Lopez et al., 2012).  
 
2.5.3.2 Non-medical management with physical exercise 
Few studies have evaluated the effect of physical exercise on cyclical symptoms and PMS. 
Among the studies found in the literature, all have demonstrated improvement in negative 
cyclical symptoms as a result of aerobic exercise (Aganoff & Boyle, 1994; Prior et al., 1997; 
Steege & Blumenthal, 1993; Stoddard et al., 2007). Unfortunately, these studies did not 
verify cycle phase by hormone analysis, but relied on self-reports or unreliable measures by 
counting days.  Furthermore, they did not use prospective daily ratings of PMS. Instead, a 
retrospective assessment was used. Aganoff & Boyle, (1994) used a cross-sectional study 
design. In addition, it should be mentioned that none of these studies were aimed at treating 
women with a medical diagnosis of PMS/PMDD. In the most recent study by Stoddard et al. 
(2007), a significant improvement was found in cyclical symptoms using a prospective study 
design comprising 14 sedentary women performing a 24-week exercise training program. 
Some analysis of hormones was performed; however, the precise procedure was not defined. 
The study group was small and had no control group.  
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2.5.4 The relation between PMS, postural control, and musculoskeletal 
injuries 
Möller-Nielsen & Hammar, (1989) have shown women with PMS to be at greater risk for 
soccer-related musculoskeletal injuries. In general, for both men and women, depressed mood 
has been suggested to be a reliable predictor to utilize in sports injuries (Galambos et al., 
2005).  
Fridén et al., (2003; 2005) have shown alterations in postural control during different 
hormonally verified phases of the menstrual cycle. Healthy women with PMS showed an 
altered postural control during the luteal phase. This difference was not seen in women 
without PMS (Fridén et al., 2003a; 2005). Abt et al., (2007); Ericksen & Gribble, (2012); 
Hariell et al., (2010), and Hertel et al., (2006) found no differences in postural control during 
different phases of the menstrual cycle. However, no ratings and analyses for PMS were done 
in any of these studies. Posthuma et al., (1987) demonstrated worse coordination during the 
luteal phase in females with PMS than in females without such symptoms. A correlation 
between low mood, anxiety, and postural control has been reported earlier (Wada et al., 2001; 
Bolmond et al., 2002). Additionally, Kitaoka et al., (2004) have studied the effects on mood 
state on anticipatory postural adjustment and shown a significant correlation between low 
mood and reaction time. The proposed mechanism has been suggested to be mood-related 
effects on central interactions of visual, vestibular, and somatosensory inputs in the 
maintenance of postural control (Wada et al., 2001; Bolmond et al., 2002). Fridén et al., 
(2003a; 2005) suggested that progesterone metabolites interact with the GABA-ergic system 
in women with PMS, causing a disturbance in postural control.  
The presence of PMS seems, as a result of transmission action within the central and 
peripheral nervous system, to be involved in disturbance of postural control and balance. It is 
unclear to what extent OC use relieves PMS and if it affects postural control in healthy 
women. This is studied in Paper I in this thesis.  
 
2.6 ORAL CONTRACEPTIVES 
Oral contraceptives are the most common reversible contraceptive method in European 
countries, with a user rate of 30–45% in fertile-aged women (Skouby, 2010). Higher 
frequencies are reported at the lower ages (Lindh et al., 2000; Skouby, 2010). In female 
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athletes, OC use is as common as in the general population (Hagmar et al., 2009). Besides 
contraception, OCs are commonly used as treatment of dysmenorrhea, bleeding disorders, 
endometriosis, and polycystic ovary syndrome (PCOS) (Fortney et al. 1986), Another 
purpose of OC treatment is time shifting of the menstrual cycle (Constantin et al., 2005).  
Combined OCs contain both an estrogen component (in most cases synthetic ethinyl 
estradiol) and a synthetic progesterone (progestagen) component which, in most OCs, are 
structurally related to testosterone (Stanczyk, 2003 review) or spironolactone for the 
progestagen drospirenone (Lopez et al., 2012). The first OCs were introduced in the 1960s 
and contained 150 μg ethinyl estradiol. The dosage has today been markedly decreased to 20–
35 μg. The different progesterone derivatives have unique biological properties and profiles 
with different metabolic effects depending on their relative binding affinity (RBA) (van 
Rooijen et al., 2002; Stanczyk, 2003 review). Progestagens with a high RBA to PR requires a 
relatively low dose to inhibit ovulation and progestagens with a high RBA to AR are known 
to produce undesirable side effects such as acne and hirsutism (Carr, 1998). However, 
combined OCs usually have anti-androgenic effects with suppression of free testosterone, 
which reduce acne and hirsutism (Stanczyk, 2003 review).  
The contraceptive effect is accomplished by suppression of the hypothalamus-pituitary 
system, induced by ethinyl estradiol and progestagen in combination. This will prevent the 
surge of GnRH, LH, and FSH, which inhibits the secretion of endogenous female sex 
hormones (E2 and P-4), thus preventing ovulation and subsequent pregnancy (Mishell et al., 
1977). In monophasic OCs, the dosage of ethinyl estradiol and the progestagen component is 
constant throughout the active treatment period, usually for 21 days, followed by seven days 
of withdrawal (menstrual bleeding) (Fig. 8) (Rapkin et al., 2006). The levels of ethinyl 
estradiol peaks about 1 h after ingestion, falls rapidly for the following six h and then slowly 
declines. Ethinyl estradiol is detectable for up to two days after discontinuation, and some 
progestagens for up to five days (Rechichi et al., 2009 review). The endogenous hormones 
that control the menstrual cycle are not completely suppressed by OCs; the levels of E2 are 
similar to the levels during the early follicular phase in a normal menstrual cycle and, during 
the withdrawal phase, the E2 levels rise (Rapkin et al., 2006; Rechichi et al., 2006). To 
achieve a more complete suppression of endogenous hormones, the withdrawn phase can be 
shortened or excluded (Rapkin et al., 2006).   
 OCs are usually well tolerated and, in a recent comprehensive study, as many as >90% of 
women on OC treatment reported high-level of satisfaction (Skouby, 2010). The most 
frequently reported side effect is depressed mood and it emerges from the progestagen 
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component in some OCs and affects some of the women. Still, for the modern OCs, the most 
serious adverse effect is venous thromboembolism, which occurs in rates of 9–10/10,000 OC- 
using women /year, comparable with a yearly incidence for non-OC users of 4–5/10,000 
women (Reid et al., 2010). The risk of hypercoagulation is estrogen-dose-dependent (Reid et 
al., 2010).  
                               
Fig. 8. Illustration displays the effects of oral contraceptives on the endogenous hormone 
production (top figure), in comparison to the regular menstruating cycle.   
 
2.6.1 Oral contraceptives in relation to neuromuscular function and 
musculoskeletal injuries 
The literature on OCs in relation to soft tissue function has shown contradictory results. OCs 
have been shown to lower the collagen fraction synthesis rate in the patellar tendon in young 
OC users, compared to non-OC users (Hansen et al., 2008). These results were explained by 
the OC-induced reduction of the bioavailability of insulin-like growth factor-I (IGF-I), which 
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has an important effect on tendon collagen synthesis (Hansen et al., 2008; Hansen et al., 
2009).  In a more recent study from the same research group, no impact of the use of OC and 
menstrual phase was found on patellar tendon morphology, biochemical composition, or 
biomechanical properties in female team handball athletes (Hansen et al., 2013). Bryant et al., 
(2008) observed strain reduction of the m. triceps surae aponeurosis during maximal 
isometric plantar flexion in OC users. Conversely, the same authors showed, in a more recent 
study, OC users to maintain dynamic control more constantly during different hopping tasks, 
compared to the non-OC users. The authors suggest that this explains the lower rate of lower 
limb musculoskeletal injuries in the OC users (Bryant et al., 2011). The use of OCs has been 
suggested to protect from ligament injuries in female athletes. Martineau et al., (2004) 
observed a significant decrease in anterior translation of the tibia (reduced laxity in the ACL) 
in female athletic OC users compared to non-OC users. Conversely, Pokoney et al., (2000) 
found no differences in ligament laxity between OC users and non-OC users. In none of these 
studies (Martineau et al., 2004; Pokoney et al., 2000) were sex hormones assessed. The 
methodology used was to count cycle days and OC use by self-report.  
Data on anaerobic power, jump performance, and muscle strength during OC use are minimal 
and have shown various results. On evaluating anaerobic power, Redman and Weatherby, 
(2004) showed a greater performance in 10-second all-out rowing during the withdrawal 
phase compared with the active treatment phase with triphasic OCs. No mechanism was 
proposed. However, this claim was refuted in other studies (Bushman et al., 2006; Giacomoni 
et al., 2000; Rechichi & Dawson, 2009), who showed no differences in anaerobic 
performance based on cycling power, jumping power, and stair climbing. Rechichi and 
Dawson, (2009) evaluated reactive strength with a drop jump test and found altered 
performance during the late withdrawal phase, compared to the active treatment phase, 
suggesting that the rise in endogenous E2 may negatively impact neuromuscular timing 
(Rechichi & Dawson, 2009). To evaluate muscle strength, four studies, comparing active OC 
treatment phase with the withdrawal phase, have failed to demonstrate any significant 
differences in maximal force-generating capacity within a monophasic OC cycle (Elliot et al., 
2005; Lebrun et al., 2003; Peters & Burrows, 2006; Sarwar et al., 1996).  
 
2.6.1.1 Training effect and injury rate with OC use 
Rickenlund et al., (2004) investigated physical performance before and after 10 months of 
OC treatment in endurance athletes and found no change in endurance capacity and strength, 
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except a small decline in performance by the beep test. In a double-blind study, Nichols et al., 
(2008) were not able to show any differences in muscle strength development during a 12-
week training program for female athletes using or not using OCs. Reiger & Yingling, (2016) 
did not demonstrate any differences in jumping height and ground reaction forces when 
comparing OC users with regularly menstruating women after a three-week jump protocol 
with five training sessions/week.  
Regarding musculoskeletal injuries and OC use, Möller-Nielsen & Hammar, (1998) have 
shown women on OC treatment to be less affected by traumatic sport injuries. Two 
epidemiological case-control studies based on two different ligament reconstruction registers 
have both demonstrated a lower likelihood of young females who use OCs to sustain an 
operatively treated ACL injury (Rahr-Wagner et al., 2014; Gray & Gugala, 2016).  
The effect of exogenous hormones in OCs on neuromuscular performance in healthy fertile- 
aged women is not fully understood. In Paper II, the effect on muscle strength and hop 
performance of OC use and hormonal variation during the menstrual cycle was evaluated.   
 
2.7 RATIONALE  
Females are reported to have a three- to six-fold higher incidence of sustaining a traumatic 
knee injury (Boden et al., 2000; Huston et al., 2000 review; Myklebust et al., 1997; Åman et 
al., 2016). Several intrinsic and extrinsic factors have been proposed to explain the 
mechanisms behind the increased injury rate. Hormonal factors have been studied to some 
extent by, e.g., observing differences in ligament laxity, neuromuscular performance, and 
muscle strength during different phases of the menstrual cycle and with OC use.  
The aim of his thesis with an experimental design was to evaluate the effects of sex hormone 
(both endogenous and exogenous) on muscle strength, postural control, and PMS in healthy 
fertile-aged women. In doing so, the results of the papers included might, to some extent, help 
to gain an understanding of the mechanisms of differences in neuromuscular performance in 
women. 
 25 
 
3 OVERALL AIM 
The overall aim of this thesis was to evaluate the influence of sex hormones and OC 
treatment on skeletal muscle function and premenstrual symptoms.  
 
3.1 SPECIFIC AIMS  
The specific aims were:  
● To evaluate the effect of OC treatment on postural control and the influence of PMS in 
physically active women (Paper I).  
 
● To evaluate and compare muscle strength in the upper and lower limb, as well as hop 
performance in active women during OC use and non-OC use in the same woman (Paper II).    
 
● To evaluate changes in premenstrual symptoms in women starting to use and discontinuing 
the use of OCs (Paper III).  
 
● To investigate mRNA and protein levels of sex steroid hormone receptors in skeletal 
muscle in three different phases of the menstrual cycle (Paper IV).  
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4 METHODS 
4.1 STUDY DESIGN 
In Papers I and IV, a prospective design was used and, in Papers II and III, a cross-over 
design was used.  
 
4.2 RECRUITMENT 
In this thesis, two different study cohorts of women were recruited. In Papers I–III, the 
participants were recruited among students at Karolinska Institutet and at the Swedish School 
of Sport and Health Sciences. In Paper IV, the subjects were recruited among students at 
Karolinska Institutet.  
 
4.3 ETHICAL APPROVAL 
The women who participated in the work on this thesis gave their written informed consent 
prior to entering the study. The papers in this thesis were approved by the Stockholm 
Regional Ethical Review Board (Dnr 2001-311 and 2006/198-31/1). These studies were 
conducted according to the Helsinki Declaration (ethical principles for medical research 
involving human subjects). 
 
4.4 INCLUSION AND EXCLUSION CRITERIA 
The inclusion criteria were: healthy women aged 20–35, non-smokers, without any regular 
medication or hormonal treatment. In Papers I–III, they were supposed to have a normal 
menstrual cycle or to use low-dose OCs and participate in moderate physical activity 
consisting of two–four sessions/week. In Paper IV, they were supposed to have a normal 
menstrual cycle and be sedentary or participate in light recreational physical activity.  
The exclusion criteria were: chronic diseases, a past or present neurological disorder, a recent 
musculoskeletal injury. 
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4.5 SAMPLE SIZE ESTIMATIONS 
In Papers I and II, the sample size calculation was based on previous studies with a clinically 
relevant difference in maximal muscle strength of 20% using a comparable methodology 
(Fridén et al., 2003; 2005). For a power of 80% with a 2-sided alpha level of 5%, 30 
participants were required, 15 in each group (OC Starters and non-OC Starters). Paper III was 
based on the same study sample as used in Papers I and II.  
In Paper IV, the sample size was based on an earlier study on ER receptor expression (Wiik 
et al., 2003). To demonstrate a hypothesized variation between menstrual cycle phases, with a 
power of 80% and a 2-sided alpha level of 5%, 20 subjects were required.  
 
4.6 PARTICIPANTS 
4.6.1 Papers I–III 
In Papers I–III, a total of 30 women received written and oral information about the study and 
filled out a health declaration form. Based on the inclusion criteria, 24 women were enrolled 
(three women did not match the inclusion criteria and another three women regretted 
participation after receiving information) and gave their written informed consent prior to 
entering the study. These 24 subjects were divided into two different groups depending on 
OC or non-OC use when entering the study. The term “OC Starters” referred to the subjects 
on OC treatment when enrolled (n = 12) and “Non-OC Starters” to the subjects who were 
menstruating normally from the start (n = 12). Fig. 9 shows a flowchart of the participants in 
three different studies, Papers I–III.  
In Papers I–III, women with both normal menstrual cycles and women on OCs were 
included. Out of the 24 subjects enrolled in the study, the OC Starters (n = 12) had been using 
low-dose monophasic OCs containing different progestagen components for at least three 
months, whereas the non-OC Starters (n = 12) were regularly menstruating. After the 
assessment in the first cycle (OC or menstrual cycle), the subjects switched to OC vs. non-
OC in a cross-over design (Fig. 8). The OC Starters discontinued their OC use and after a 
wash-out period of one to three months the OC Starters then continued the study protocol 
with assessments during a normal menstrual cycle (non-OC cycle). The non-OC Starters, 
were instead prescribed low-dose monophasic OCs and were assessed at the start of the use 
of the second pill chart (OC cycle). 
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All women were using low-dose monophasic OCs of a similar type (Table 1). The regimen 
for the OC treatment was 21days of active hormone treatment followed by seven days of 
withdrawal (no active hormone). Screening for contraindications of OC treatment was based 
on anamnestic data of risk for thromboembolism and blood pressure measurement prior to 
prescribing OCs.  
 
Table 1. The different types of monophasic OCs used in the present thesis (n = 19). 
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Fig. 9. Flowchart for Papers I–III.  
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4.6.2 Paper IV 
In Paper IV, all women enrolled (n = 36) had normal menstrual cycles, received written and 
oral information about the study, and filled out a health declaration form. Based upon the 
inclusions criteria, 30 women were enrolled in the study. For data collection, the women were 
divided according to three different schedules during a period of three menstrual cycles (Fig. 
10). The characteristics of the enrolled participants of the two different cohorts (n=24 and 
n=30) are presented in Table 2.  
 
 
Table 2. Characteristics of the participating women of cohort I for Paper I-III (n = 24), 
divided into regard to entering the study with OCs or without OCs and cohort II for 
Paper IV (n = 30). 
Cohort 2
OC Starters (n = 12) Non-OC Starters (n = 12) (n = 30)
Age (yrs) 24.6 (2.5) 27.0 (4.8) 29.0 (1.4)
Height (cm) 164.5 (6.3) 166.8 (5.2) 167.5 (3.5)
Weight (kg) 61.9 (9.4) 61.8 (6.5) 61.8 (1.8)
BMI (kg/m2) 23.7 (6.9) 23.1 (1.1) 21.9 (1.6)
Physical ativity level 
(session/ week)
Values in mean (SD)
Abbriviation: BMI (Body mass index)
Cohort 1
3.1 (1.1) 2.1 (1.1)
 
 32 
 
 
 
Fig. 10. Study protocol and sample size for Paper IV. The subjects were divided according to 
three different schedules, for each schedule (n = 10), one muscle biopsy specimen was 
collected in one specific phase per cycle.                         
Abbreviations: (FP) follicular phase, (OP)  ovulation phase, (LP) luteal phase.  
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4.7 PROCEDURS 
4.7.1 Procedure, Paper I 
Prior to the assessments, all subjects performed three familiarizations trials on separate 
occasions in order to get used to the equipment and the test procedure of physical 
performance, as well as to avoid learning effects. The subjects were tested for postural control 
during three different occasions on the pill chart in one OC cycle. The first test session was at 
days 3–5 in the withdrawal phase (non-OC phase), the second test session was during days 7–
8 on the pill chart (OC phase) and the third test session was on days 14–15 on the pill chart 
(OC phase). The two latter occasions were then calculated together as one OC phase since the 
hormonal status is equal in the OC phase.  
Based on the results of the PMS screening (see below), the subjects were divided into a PMS 
group and a non-PMS group.  
 
4.7.2 Cyclicity diagnosis 
Prospective ratings of PMS were used in Paper II and Paper III during the OC cycle and non-
OC cycles for both groups (OC Starters and Non-OC Starters). A previous validated cyclicity 
diagnostic tool, the Cyclicity Diagnoser (CD), was used (Sundström et al., 1999). The 
subjects were supposed to rate their symptoms every evening during the test period. The CD 
scale, which complies with the description in the World Health Organization International 
Classification of Diseases (ICD-10) and the American Collage of Obstetrics and Gynecology 
(ACOG) (WHO, 1996; ACOG, 2000) criteria for PMS and with the DSM IV (APA, 1994) 
criteria for PMDD, consists of four negative mood parameters (depression, fatigue, 
irritability, and tension), two positive mood parameters (friendliness and energy) and three 
somatic symptoms (swelling/bloating, breast tenderness and menstrual bleeding). In addition, 
the CD scale consists of scores for measuring various effects on daily life using seven 
different parameters: appetite, activity of daily life, general impairment of daily life, sleeping 
disorders, temprament, difficulty in concentrating, and feeling out of control (Fig. 11). 
 
The CD scale is a nonparametric Likert scale with a range of 0–8, with 0 indicating the 
absolute absence of a particular symptom and 8 the maximal severety of the symptom. A 
significant increase in at least one negative mood symptom and/or somatic symptom during 
the cycle during the premenstrual days, days 24–28 and days 1–2, compared with cycle days 
4–10, indicates PMS (referens). 
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Fig. 11. The different modules of PMS described in the CD scale, used in this thesis.  
 
4.7.3 Procedure, Paper II  
After the subjects had performed three familiarizations trials on separate occasions, they were 
tested in two hormonally different cycles: a normal menstrual cycle (non-OC cycle) and an 
OC cycle.  
For the non-OC cycle, the first test session was in the follicular phase (FP) (cycle days 3–5). 
The second test session in the non-OC cycle was in the ovulatory phase (OP), which was 
detected by an LH surge in urine. After detection of an LH surge, the subject was assessed 
within 24–48 h. The third test session was in the luteal phase, which was defined as seven 
days after ovulation with a simultaneous increase in serum progesterone.  
For the OC cycle, the first test session was on days 3–5 in the withdrawal phase (non-OC 
phase). The second test session was during days 7–8 on the pill chart (OC phase) and the 
third test session was on days 14–15 on the pill chart (OC phase). 
In order to minimize diurnal variation, the assessments were performed at the same time of 
day at each session. 
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4.7.4 Procedure, Paper III 
The results in Paper III were based on the CD scales, together with serum analyses as 
described in Paper II.  
 
4.7.5 Procedure, Paper IV 
Regularly menstruating women were included in Paper IV. The protocol for blood sampling 
and collection of muscle biopsy specimens at three different phases during three consecutive 
menstrual cycles is illustrated in Fig. 12. The first assessment was in the follicular phase (FP) 
(cycle days 3–5). The second assessment was in the ovulatory phase (OP), which was 
detected by an LH surge in the urine. The third assessment was in the luteal phase (LP), 
which was defined as occurring seven days after ovulation with a simultaneous increase in 
serum progesterone.  
 
 
Fig. 12. The protocol for blood sampling and muscle biopsy specimen collection followed 
three different schedules with one assay in different phases of each menstrual cycle.  
 
4.8 DROP OUTS  
In Paper I, seven participants dropped out: four due to missing values on the force platform; 
two did not show totally clear hormone levels, and one for personal reasons (Fig. 9).  
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In Paper II, seven participants dropped out: three due to failure to detect ovulation during the 
non-OC cycle, two did not show totally clear hormone levels, and two for personal reasons 
(Fig. 9).  
In Paper III, five participants dropped out: three due to failure to detect ovulation during the 
non-OC cycle, two for personal reasons (Fig. 9).  
In Paper IV, 14 participants dropped out: four due to failure to detect ovulation, nine had an 
unpleasant biopsy and one for personal reasons (Fig. 10). 
 
4.9 DATA COLLECTION 
4.9.1 Blood sampling and analyses 
In all Papers of the present thesis blood samples for determination of hormone levels were 
collected in the morning after 15 min of rest before every test occasion. After centrifugation, 
serum was separated and stored at -20°C until analyzed. E2, P-4, and SHBG were analyzed in 
serum using chemiluminescent enzyme immune-metric assays (IMMULITE Automated 
Analyser, DPC). Serum levels of T were determined by radioimmunoassay using a 
commercial kit obtained from Diagnostic Products Corp (Coat-account
®
 Testosterone, Los 
Angeles, CA). Apparent concentrations of free T were calculated from values of total T, fixed 
albumin concentration of 40g/L by successive approximation using computer program based 
on equation derived from the law of mass action (Södergård et al., 1982). Detection limits 
and coefficients of variation were standardized for each hormone. For a more detailed 
description of the serum analyses, see the Method section in each of the respective Paper I-
IV.  
 
4.9.2 Measurement of postural control  
Measurements on an AMTI® force platform were used to evaluate postural control in a quiet 
stance, expressed as displacement of CoP. Subjects were asked to stand barefoot in a 
comfortable one-legged stance on a marker at the center of the platform. Postural control was 
measured for one minute. The subjects stood quietly with the arms relaxed and with the non-
supported leg flexed to 90° at the knee, with their eyes focused on a target placed at eye level 
approximately 2 m in front of them (Fig. 13). If the arms were used for balancing, subjects 
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were asked to correct the position as soon as possible. Three trials, one for each leg, were 
performed, with a one-minute break with the subject resting in a chair. All experiments were 
performed in a quiet room and in the same order at each test session.  
 
Fig.13. Measurements of postural control on an AMTI® force platform (model LG6-4-2000, 
Advanced Mechanical Technology, Inc., Watertown, MA, USA).  
 
Ground reaction force data were sampled at 50 Hz and the AMTI MSA-6 amplifier system 
was used together with a PC and an analogue data actuation system. The force platform 
measured three force components, Fx, F,y and Fz, and three moment components, Mx, My, 
and Mz  (x, y, and z are the medio-lateral (x), anterior-posterior (y), and the vertical (z) 
directions) (Fig. 14).  
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Fig. 14. Illustrates the force components (Fx, Fy, and Fz ), together with the moment 
components (Mx, My, and Mz), measured using the force platform.  
 
The CoP position was calculated as follows:  
 CoPx = [(My + (Zoff * Fx)) / Fz ] * (-1) 
 CoPy = [(My - (Zoff * Fy)) / Fz ] 
Where Zoff = the vertical offset from the top plate to the origin of the force 
platform (a negative #).  
The CoP datum is given as a location (two-dimensional) on the surface of the force plate. 
These two coordinates are identified in relation to the orientation of the subject: anterior-
posterior (a-p) direction and medio-lateral (m-l) direction.  
 
4.9.2.1 Data analysis of measurements on force platform 
To study in detail the CoP displacements, total displacement (dCoP) in the a-p and m-l 
directions and the area encompassed by the CoP displacement trace were analyzed. These 
characteristics were computed off-line using the software of MATLAB
® 
(The Math Works, 
Inc. Natick, MA, USA). The area was computed using the ellipse area method and the 
principal axes of the ellipse were determined by the principal-component analysis (PCA) 
(Oliveira et al., 1996). Subtotals of 85.35% of samples lie within the perimeter of an ellipse 
when using this method (Papoulis, 1984).  
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4.9.3 Measurements of muscle strength and hop performance  
4.9.3.1 Isokinetic muscle torque 
A standardized isokinetic device (Biodex
®
, Corp, Shirley, NY, USA) was used for 
measurements of maximal muscle torque (Nm) in the leg extensor muscles. This device has 
been tested previously for mechanical reliability with good results and, concerning the 
validity of isometric torque and position measurements, the Biodex
®
 device was 
considered acceptable for both clinical and research purposes at velocities below 
300°/seconds (Drouin et al., 2004).  
The subjects sat upright with the back supported, at a hip angle of 85°. Trunk and hips were 
stabilized with straps. The lever was attached just above the ankle and the axis of rotation was 
aligned with the center of the femoral condyles (estimation by palpation). Fig.15 illustrates 
the test position. The knee extensor muscles of the right leg were measured at 120°/seconds, 
in a range of motion (RoM) of 90°–10° of knee flexion. Five consecutive concentric 
contractions were performed and the peak torque of the best contraction was recorded.  
 
 
Fig. 15. Measurement of maximal isokinetic muscle strength of the leg extensor muscles 
using a Biodex device (Biodex® Corp, Shirley, NY, USA).            
Picture adapted with the kind permission from the manufacture at biodex.com.  
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4.9.3.2 Handgrip strength 
The dominant hand was tested for handgrip strength with a handgrip strength dynamometer 
(Jamar
®
, Sammons Preston, Bolingbrook, IL, USA).  This device has been tested previously 
for reliability (inter- and intra-test reliability, r = 0.98 and r = 0.94- 0.98, respectively) 
(Peolsson et al., 2001). The subjects were tested for handgrip strength with the arms hanging 
along the side of the body. The best result (in kg) of three trials was recorded.  
 
4.9.3.3 One-leg hop test 
The one-leg hop test was used to measure explosive muscular power. This test was originally 
described by Tegner et al., (1986) and a modified version allowing the use of arms to 
accelerating the jump was described later (Zetterström et al., 1992). The one-leg hop test has 
shown great test-retest reliability: ICC, r = 0.96 (Ageberg et al., 1998). The test is performed 
by jumping off and landing on the dominate leg (right leg in all cases in this thesis) with 
maintained control of posture and orientation. The best jump out of at least three trials was 
recorded (until no increase in hop length was seen). Fig. 16 illustrates the performance.  
 
Fig. 16. Illustration of the start and stop position of the one-leg hop test. The subject jumps 
off and lands on the same leg, with maintained control of posture and orientation.  
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4.9.4 Muscle biopsy collection and analyses  
The muscle biopsy specimen was collected from the m. vastus lateralis of the quadriceps 
muscle, in rest and using a percutaneous needle biopsy technique. The collection of biopsy 
specimens was done in three consecutive menstrual cycles and followed a structured schedule 
(Fig. 12) where one biopsy specimen was collected each month during three different phases 
of the menstrual cycle in each subject. After the collection, all samples were immediately 
cooled in liquid nitrogen and frozen in isopentane and stored at –80oC until analyzed.  
In order to extract the RNA from the muscle biopsy specimen, a purification procedure was 
applied using a combination of Trizol reagent and RNeasy Clean Up Kit (Qiagen, Hilden, 
Germany). Specific management is described in the published paper (Ekenros et al., 2016). 
Total RNA was purified using the RNeasy Clean Up Kit (Qiagen) according to the 
manufacturer’s instructions. One hundred nanograms of total RNA from each sample were 
then reverse transcripted into cDNA using TaqMan Reverse Transcription Reagents (Applies 
Biosystems, Stockholm, Sweden) with random hexamer primers. Real-time (RT) PCR assays 
were conducted using the Applied Biosystems 7500 fast RT-PCR system with SYBR green 
master mix RT-PCR reagent (Applied Biosystems). All RT-PCRs were performed in 
duplicate. Acidic ribosomal phosphoprotein PO (36B4) was used as an internal control gene 
(Akamine et al., 2007).  
An enzyme-linked immunosorbent assay (ELISA) was used to determine protein levels of 
hormone receptors. The tissue homogenization procedure was carried out. Approximately 
200 mg of muscle tissue were homogenized with 1 mL of ice-cold lysis buffer (see Ekenros 
et al., 2016 for more details). Tissue extracts were prepared by centrifugation at 10,000 g for 
10 min at 4°C. The protein concentration of the tissue extract was calculated using the 
Bradford assay method (Bio-Rad Hercules, CA, USA). 20 µg protein was used for the 
determination of ERα protein levels, while 30 µg protein was used for the determination of 
PR and AR protein levels. In all cases, NR Sandwich ELISA by Active Motif was used 
according to the manufacturer’s instructions.  
 
4.10  DATA ANALYSIS   
Statistical tests and analysis and assembling of descriptive data were performed using the 
STATISTICA software (Statsoft, version 12, Tulsa, OK, USA) and the Statistical Package for 
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the Social Sciences (SPSS) (SPSS Inc, version 17, Chicago,IL, USA). Table 3 lists the 
descriptive statistics and statistical analyses in the present thesis. 
 
In Papers II and III an idealization of cycle length was done in order to make comparable 
cycle lengths when analyzing the CD scales. The menstrual cycle length was therefore 
idealized to 28 days in all regularly menstruating women. The most critical days to be 
measured were cycle days 3–5 (early follicular phase), days 12–24 h after the LH surge 
(ovulation phase) and 7 days after ovulation (mid-luteal phase). Preovulatory days were cut 
out in women with menstual cycles longer than 28 days. In cases where the menstrual cycle 
was shorter than 28 days, the cycle was extended with preovulatory days.  
 
 
Table 3. The statistical methods used in the respective Papers of this tesis.  
Paper I Paper II Paper III Paper IV
Descriptive statistics 
Mean ● ● ● ●
Standard deviation ● ● ● ●
Median ● ● ●
Standard error of mean ● ●
IQR 25th - 75th percentile ● ●
Min-Max ● ● ● ●
Statistical methods
Mann Whitney U-test ● ●
Wilcoxon Rank Sum Test ●
Pearsons Corr. Coefficient ●
Spearman Rank Corr. ●
Repeated ANOVA ● ● ●
Mixed models ANOVA ●
Fisher post Hoc ● ● ●
 
Abbreviations: (IQR) Interquartile range, (Min) Minimum, (Max) Maximum, (Corr.) Correlation, (ANOVA) Analyze of 
varians 
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4.10.1.1 Paper I 
The Mann-Whitney U-test was used to analyze each symptom on the CD scale and to identify 
women with cyclicity (Hammarbäck et al., 1989). Postural control data were analyzed using 
repeated measures analysis of variance (ANOVA). The Fisher post hoc test for multiple 
comparisons was used to assess differences between groups and phases.  
 
4.10.1.2 Paper II 
Analyses of muscle strength between groups and between phases within groups were 
performed using ANOVA.  
 
4.10.1.3 Paper III 
The Mann-Whitney U-test was used to analyze each symptom on the CD scale and to identify 
women with cyclicity (Hammarbäck et al., 1989). The Chi-square test was used to detect 
changes in the number of women with cyclicity between cycles. The Wilcoxon rank sum test 
was used to analyze the difference between the menstrual and premenstrual phases. Group 
data were further analyzed by ANOVA, comparing the seven days in the menstrual phase 
with the seven days in the premenstrual phase during the non- OC cycle vs. the OC cycle. 
The Fisher post hoc test for multiple comparisons was used to assess differences between the 
non-OC cycle and the OC cycle.  
 
4.10.1.4 Paper IV  
A mixed model was used with phase as a within-group factor and three levels (FP, OP, and 
LP). Correlations were performed using the Pearson correlation coefficient as well as the 
Spearmann rank correlation. All tests were two-sided and the level of significance was set at 
0.05. 
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5 RESULTS AND DISCUSSION 
The main results are presented in this section; please see each publication and manuscript for 
detailed results.  
 
5.1 OVERALL FINDINGS 
The overall purpose of this thesis was to explore postural control and muscle function in 
relation to sex hormones and PMS. The thesis comprises four papers on the basis of which the 
main findings will be reviewed and discussed.  
The main findings were: 
● Postural control was altered in women with PMS on OC treatment compared to women on 
OC treatment without such symptoms.  
● Treatment with OCs did not have an acute effect on muscle strength and hop performance in 
physically active women.  
● Treatment with OCs reduced somatic PMS but had no effect on mood symptoms in this group 
of healthy regularly exercising women.  
● Variations in mRNA and protein levels of ERα and PR were detected in skeletal muscle 
during the follicular, ovulatory, and luteal phase, respectively. However, no variation in AR was 
detected across the menstrual cycle. 
 
5.2 HORMONE DETERMINATION 
During the normal menstrual cycle (the non-OC cycle), the hormone levels in serum confirmed 
the different phases of the menstrual cycle (FP, OP, and LP). Serum analyses of endogenous 
hormone levels during the OC cycle were low, as expected, which confirmed the intake of OCs. 
The exogenous hormones in OCs are not measured in serum analysis. The hormone levels are 
displayed in Table 4.  
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Table 4. Mean (SD) of hormone levels during three phases in the normal menstrual cycle (non-
OC cycle) and during the OC cycle (n = 19). 
 
     
               Normal menstrual cycle (non-OC cycle)                               OC cycle  
  
 
           FP     OP      LP         Withdrawal     Pill day 7-8   Pill day 14-15 
 
FSH(mlU/ml)      6.5 (1.9)   7.4 (3.6)  3.6 (2.4)            5.9 (3.0)            4.5 (3.6)         2.3 (1.9) 
 
LH(mlU/ml)          4.7 (1.4) 10.9 (7.0)  3.7 (1.9)          3.7 (1.8)            5.0 (3.4)         2.2 (2.8) 
 
E2(pmol/l)          114 (30.5) 268 (171) 403 (220)        100 (43.7)          109 (23.7)        289 (274) 
 
P-4(nmol/l)            1.7 (1.4)   8.3 (7.1) 36.5 (19.4)         1.2 (0.3)           1.2 (0.3)         1.4 (0.4) 
 
SHBG(nmol/l)    55.0 (18.0) 53.7 (16.0) 57.2 (16.0)        110 (62.8)         107 (63.4)         117 (69) 
  
Abbreviations: FP (follicular phase), OP (ovulation phase), LP (luteal phase), FSH (follicle stimulating 
hormone), LH (luteinizing hormone), E2 (estradiol), P-4 (progesterone), SHBG (sex hormone-binding globulin) 
 
 
5.3 POSTURAL CONTROL 
In Paper I, an altered postural control during the OC phase in women with PMS (n = 6) was 
demonstrated. However, there was no difference in postural control in women without such 
symptoms (n = 9). Results from the CD scale showed that six women had a significant increase 
in somatic and negative mood symptoms during the OC phase, compared to the non-OC phase 
(PMS group), whereas nine women did not show any cyclical changes between the phases (non-
PMS group). Negative mood symptoms dominated over somatic symptoms in the PMS group 
(Fig. 17).  
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Fig. 17. Mean negative mood scores during a treatment cycle in the PMS group (n = 6) and the 
non-PMS group (n = 9) respectively. 
 
Measurements of postural control on the force platform demonstrated a significant interaction (p 
< 0.05) between phase and group. In the PMS group, the displacement area (cm
2
) was 
significantly greater in the OC phase, compared to the non-OC phase (Fig.18). In the non-PMS 
group, no significant difference between phases was observed.  A significantly greater 
displacement area was shown in the PMS group, compared to the non-PMS group, in the OC 
phase (p < 0.05). No difference between groups was found in the non-OC phase (Fig. 16).  
 
Fig. 18. Mean (SEM) displacement area during the non-OC phase and the OC phase of an OC 
cycle in the PMS group (n = 6) and the non-PMS group (n = 9), respectively.  
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5.3.1 Postural control in relation to sex hormones and PMS 
Fridén et al., (2003a; 2005) studied regularly menstruating women during three different phases 
of the menstrual cycle and demonstrated that women with PMS had an altered postural control 
during the luteal phase, compared to the follicular phase and ovulatory phases. This difference 
in postural control was only seen in women with PMS. Darlington et al. (2001) detected a 
greater displacement in the luteal phase and in the early follicular phase. In this study the 
influence of PMS was not evaluated. Later, studies on postural control during different phases 
of the menstrual cycle have not been able to show any differences in postural control (Abt et al., 
2007; Hertel et al., 2006; Harriell et al., 2010; Ericksen & Gribble, 2012). However, ratings of 
PMS were not performed in those studies.  
Variations in E2 and P-4 levels during the menstrual cycle are known to affect the CNS 
(McEwen 2002). The progesterone metabolite and neurotransmitter, allopregnanolone, acts as a 
positive modulator of the GABA-A receptor, similar to the action of benzodiazepines (Gee et 
al., 1987; Majewska et al., 1986). Benzodiazepines and allopregnanolone have been reported to 
have several negative effects, including drowsiness, concentration difficulties, motor in- 
coordination, muscle weakness, and memory impairment (Holbrook et al., 2000; Longo & 
Johnson, 2000; Sundstrom et al., 1999). Söderpalm et al., (2004) demonstrated a mild sedative 
effect of allopregnanolone, with impairment of smooth eye pursuit movement and self-reported 
fatigue in both men and women. In an animal study, Tamarova et al., (2007) showed a reduction 
in postural adjustment when the inhibitory GABA-A receptor in the brain was modulated, 
suggesting a connection between GABA-A receptor activation and postural control. Besides, 
modulation of GABA-A has, in some individuals (those with severe PMS), been shown to cause 
low mood, irritability, and anxiety (Bäckström et al., 2014 review). Low mood and anxiety have 
been suggested earlier to correlate with altered postural control (Bolmont et al., 2002; Wada et 
al., 2001). In addition, mood states have been shown to alter the reaction time on anticipatory 
postural adjustment (Kitaoka et al., 2004).  
In the present thesis, some of the women showed PMS despite OC use. Negative mood 
symptoms were shown to dominate over somatic symptoms in this group. This is in agreement 
with OC treatment studies on PMS, where somatic symptoms have been shown to be relieved 
and mood symptoms remained (Bäckström et al., 1992). In the present thesis, serum levels of 
endogenous E2, P-4, and T were low during OC treatment, as expected. The exogenous 
hormones, e.g., the progestagen component in OCs, may, in some women, trigger the negative 
mood symptom, as proposed for the natural P-4 and its metabolites (Bäckström et al., 2003).  
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5.3.1.1 Measurements of postural control 
In Paper I, only women on OC treatment were included and divided into two groups: PMS and 
non-PMS. Postural control was evaluated in a one-legged stance on an AMTI
®
 force platform. 
Measurements with objective stabilometry using force platforms are considered to be the golden 
standard with acceptable test-retest reliability (Ekdahl et al., 1989). A significant increase in the 
displacement area was demonstrated in the women with PMS during the OC phase (active 
pills), but not during the non-OC phase (withdrawal phase) and no difference was detected 
between phases in the women without PMS. However, when measuring postural control in a 
sports medicine context it is important to understand its complexity. Research suggests an 
individual nonlinear relationship between dynamic stability and the degree of performance and 
pathology for both females and males. The individual strategy for managing a particular motor 
task can vary greatly and has been suggested to be a cornerstone for understanding adaptable 
physiological systems (van Emmerik & van Wegen, 2002 review; Lipsitz, 2002). For example, 
no relationship between the strategy of balance in quiet one-legged stance and the strategy used 
in more complex and dynamic tasks, such as the star excursion balance test (Wikström et al., 
2006 review) or in a single-leg landing from jumping task (Sell, 2012), has been demonstrated 
in the literature. Furthermore, there is still limited evidence to support that altered balance in the 
one-legged stance correlates with an increased risk of musculoskeletal injuries in the lower 
extremity (Steffen et al., 2016; Söderman et al., 2002; Tropp et al., 1984). However, there 
seems to be some correlation since several studies have shown proprioceptive balance training 
to be an effective prevention strategy for specific injuries in specific sports (in both males and 
females) (Bahr et al., 1997; Wester et al., 1996; Wedderkopp et al., 1999). No validated 
measurement of static or dynamic balance was performed, however, in the above referred 
studies at baseline or following the intervention. This makes it unclear whether the intervention 
of balance training directly affected balancing ability.  
 
5.3.1 Altered postural control in relation to musculoskeletal injuries in 
females 
To consider altered balance as a risk factor for musculoskeletal injuries seems to be 
controversial. The literature suggests that humans have wide individual spectra when it comes 
to different strategies to solve different balance tasks (Wikström et al., 2006 review). One could 
expect, however, that within the same individual and the same balance task, one could expect 
the same pattern for test and re-test. In the present thesis (Paper I), a difference in postural 
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control strategies was demonstrated in the same women, with a greater displacement area 
correlating with cyclical symptoms of negative mood. Studies on neuromuscular characteristics 
measured by means of kinematics and kinetics have failed to show any differences in jumping 
and landing patterns in women during different, serum-verified phases of the menstrual cycle 
(Chaudhari et al., 2007; Abt et al., 2007) or on different occasions during an OC cycle 
(Chaudhari et al., 2007). In a prospective study of 838 basketball and soccer players, Steffen et 
al., (2016) found, no significant difference in sway velocity, excursion, or dynamic balance 
between injured and uninjured female elite athletes. 
Training programs aimed at enhancing neuromuscular function and proprioception to prevent 
musculoskeletal injuries have shown promising results in reducing ACL injuries among female 
athletes (Hewett et al., 2000 review; Mandelbaum et al., 2005; Myklebust et al., 2003).  
 
5.4 MUSCLE STRENGTH AND SEX HORMONES 
The aim of Paper II was to compare muscle strength and hop performance in women on OC 
treatment (OC cycle) with the same women during the normal menstrual cycle (non-OC cycle). 
The outcome showed no overall differences between the OC cycle and the non-OC cycle. The 
results for isokinetic muscle strength in the knee extensors (peak torque) showed no difference 
between the respective cycles (p = 0.78) (Fig. 19).  Similar findings of no significant differences 
in the different cycles were noted for measurements of handgrip strength (p = 0.76) and for the 
one-leg hop test (p = 0.78) (Fig. 20). 
There were no differences in any of the parameters of strength between the different phases in 
the OC cycle (active hormone phase vs. withdrawal) or within the phases in the non-OC cycle, 
apart from a significant increase in peak torque in the luteal phase, compared to the follicular 
phase.  
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Fig. 19-20. Illustrates the result for isokinetic muscle strength (peak torque) in the knee 
extensors (Nm) and the performance of the one-leg hop test (centimeters). There were no 
significant differences in any of the evaluated parameters between the OC cycle and non-OC 
cycle.  
 
The influence of female endogenous and exogenous sex steroids on neuromuscular function has 
been debated. Estrogen has been suggested to have anabolic effects on the skeletal muscle that 
may be explained by energy metabolism properties (Enns & Tiidus, 2010 review). Estrogen has 
been assumed to promote glycogen uptake and storage in the liver and skeletal muscles through 
increased lipid synthesis and enhanced lipolysis in the skeletal muscle (Braun & Horton, 2001). 
In the present thesis (Paper II), the endogenous, as well as the exogenous, sex hormones did not 
have any effect on skeletal muscle function with regard to strength and hop performance. These 
findings support previous studies on muscle strength in relation to OC use which suggest no 
difference in strength connected with OC treatment (Elliot et al., 2005; Lebrun et al., 2003; 
Ruzic et al., 2003). Elliot et al., (2005) studied 14 women on monophasic OC use and found no 
significant difference in maximal force production of the dorsal interosseous muscle. Lebrun et 
al., (2003) used the triphasic OC formulation in a study on 14 physically active women and 
were not able to show any significant difference in isokinetic muscle strength during OC 
treatment. However, Philips et al., (1996) showed that OC users had a significant increase in 
maximal force production in the adductor pollicis over a six-month training period, compared to 
non-OC users. Although the progestagen component in different OC formulations varies in its 
potency and androgenocity, OC use might be able to affect soft tissue and muscle strength. 
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Overall, it seems that the androgenic component is not large enough to influence muscle 
strength. The progestagen levonorgestrel, which belongs to the more androgenic type, was 
the most frequently used one (n=10) in the present thesis. Due to the small sample size, no 
stratification was performed on each OC formulation (Paper II). Since no conclusions 
regarding different OC formulations and muscle strength can be drawn, the choice of OC is still 
open to the particular female athlete.  
In healthy, fertile-aged women, ingestion of OCs does not seem to have any effect on skeletal 
muscle strength. In animal studies, however, estrogen has been shown to possibly have an 
anabolic effect on skeletal muscle strength (Enns & Tiidus, 2010 review; Skelton et al., 1999). 
Additionally, in women with a low estrogenic state, as in postmenopausal women, replacement 
therapy of estrogens might have anabolic effects on muscle strength (Ronkainen et al., 2009; 
Dieli-Conwright et al., 2009). 
Intensified strength training during the follicular phase (elevated levels of E2) has been 
suggested to have a positive effect on muscle strength in physically active women, compared to 
the same training protocol during the luteal phase (Reis et al., 1995; Sung et al., 2014; 
Wikström-Frisén et al., 2015). In a study by Wikström-Frisén et al., (2015,) no division into 
groups was done. Non-OC users and OC users (both monophasic and triphasic) were clustered 
and analyzed together. Mono- and triphasic OCs differs in the amount ethinyl estradiol and 
progestagen across the pill chart. Monophasic OCs have a constant hormone level while 
triphasic OCs vary in the hormone levels aimed a mimicking the natural menstrual cycle 
(Redman & Weatherby, 2004).  Apart from the proposed estrogenic effect in the follicular 
phase, it can be speculated if cyclical symptoms in the luteal phase, which are experienced by 
more than 75% of fertile-aged women, would have an effect on the results. The mental states of, 
e.g., fatigue, lack of interest, and lack of concentration, might influence the motivation to train 
hard and, consequently, lead to a defaulted gain in muscle strength.  
 
5.5 ORAL CONTRACEPTIVES AND PMS 
To the best of our knowledge, Paper III is the first prospective study of PMS in healthy, 
physically active women switching from not using OC to OC treatment or vice versa. The 
results of  Paper III showed an overall (n = 19) significantly (p <0.05) higher rating of somatic 
symptoms during the premenstrual phase (seven days) in the normal menstrual cycle (non-OC), 
compared to the corresponding seven days in the OC cycle (Fig. 21). In contrast, the negative 
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mood scores did not differ between the two cycles (Fig. 22). Negative mood symptoms are, in 
general, less common regardless of OC treatment or non-OC treatment, which was also found in 
the present study in agreement with Sveinsdóttir and Bäckström, (2000).The progestagen 
component in OCs inhibits ovulation by a feed-back mechanism on the pituitary. The formation 
of the corpus luteum fails, which results in a reduced plasma concentration of neurosteroids in 
the brain (REF). Still, a subset of women on OCs experience negative mood symptoms, 
hypothetically due to a similar effect of the progestagens in the brain (REF).  
  
Fig. 21-22. Illustrates the symptom scoring for summarized somatic symptoms and for 
summarized negative mood symptoms in the entire study group (n = 19) during the normal 
menstrual cycle and the OC cycle, respectively.  
 
The results of PMS in the Non-OC Starters (n = 11) and OC Starters (n = 8) showed that 8 out 
of 11 women among the Non-OC Starters had PMS of a somatic type (p <0.05) during the 
normal menstrual cycle. After having switched to OC treatment, only 4 out of 11 still showed 
PMS in symptoms of the somatic type (p = 0.09). Fig. 23 illustrates the summarized somatic 
symptoms in one woman showing PMS during the normal menstrual cycle, but not during the 
following OC cycle. In contrast, the negative mood symptoms did not change between the 
normal menstrual cycle and the OC cycle.  
Among the OC Starters, 2 out of 8 women showed PMS in symptoms of the somatic type 
during the OC cycle. After washout, there was no change in symptoms scores in the normal 
menstrual cycle. For the symptoms of negative mood, the proportion of women showing PMS 
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in the OC cycle was 2 out of 8. After washout, a proportion of 4 out of 8 women showed 
negative mood symptoms in the normal menstrual cycle (ns).  
                                                            
Fig. 23. Illustrates the summarized somatic symptoms scores for one woman among the Non-
OC Starters.The premenstrual days were set to cycle days 24–28 and days 1–2 (total, 7 days).  
 
Only a few randomized controlled trails have been published that evaluate the effect of OC on 
PMS (Graham & Sherwin, 1992; Bancroft & Rennie, 1993), and with conflicting results. The 
treatment effect of combined OCs on PMS and PMDD seems to be dependent on the type of 
progestagen, the dosage of ethinyl estradiol, and the treatment regimen. In the present study, a 
variety of OCs were used with different dosages of ethinyl estradiol (25–30 μg) and with 
different types of progestagen (levonorgestrel, noretisteron, norgestimat, drospirenone, and 
desogestrel combined with lynestrenol) and in a 21/7 regimen. A Cochrane review aimed at 
evaluating the relatively novel progestin, drospirenone, has shown a reduction in somatic PMS 
as well as in negative mood symptoms in both women with PMS and PMDD (Lopez et al., 
2012). Compared to other progestagens, drospirenone has anti-androgene and anti-aldosterone 
properties (Yonkers et al., 2005; Pearlstein et al., 2005). Furthermore, in a recent study, the 
progestagen norgestimate, combined with 35 μg ethinyl estradiol, has been shown to improve 
both somatic and mood symptoms in women with mild to severe PMS (Nyberg, 2013). In a 
review of continuous (no withdrawal) OC treatment with levonorgestrel and 20 μg ethinyl 
estradiol, a non-consistent treatment effect on the treatment of PMS and PMDD was 
demonstrated (Freeman et al., 2012). The regimen of 24 active-pill and 4 pill-free days has been 
shown to be more effective for reducing cycle-related symptoms, compared to the traditional 
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21/7 regimen, due to  more complete suppression of ovarian activity and a lower release of 
endogenous FSH, E2, and P-4 (Yonkers et al., 2008).  
In a sport- related perspective, the use of OC does not guarantee total relief of PMS.  Women 
respond differently to different progestagens: some are still left with negative mood symptoms, 
even after some month or so of treatment, and some respond well, with a stabilized effect on 
both mood and somatic symptoms. The psychological negative mood symptoms may possibly 
affect the performance in sports and trainability. Some literature suggests a lower injury rate in 
females using OCs, compared to those who not use OCs (Gray & Gugala, 2016; Möller-Nielsen 
& Hammar, 1998; Rahr-Wagner et al., 2014).  
 
5.5.1.1 Effects of physical aerobic exercise on low mood 
Physical activity has the capacity to promote synaptic and functional plasticity in the brain and 
spinal cord (Vaynman & Gomez-Pinilla, 2005 review). Endurance exercise in particular has 
been shown to be effective for alleviating depressed mood (Vaynman & Gomez-Pinilla, 2005 
review). Tozzi et al., (2016) showed in a prospective study that 16 weeks of aerobic exercise, 
twice a week, significantly reduced depressed mood and improved well-being in healthy men 
and women. According to a magnetic resonance imaging (MRI) evaluation, the improvements 
in mood were related to a strengthening of connectivity in the functional brain region that 
regulates mood. They also demonstrated a dose-dependent response (Tozzi et al., 2016). 
Literature on PMS and exercise (Aganoff & Boyle, 1994; Prior et al., 1997; Steege & 
Blumenthal, 1992; Stoddard et al., 2007) suggests an improvement of cyclical symptoms with 
regular aerobic exercises in sedentary females. However, the underlying mechanism of the 
improvement was not studied and it remains unclear whether exercise affects the PMS or 
whether it is the effect of well-being due to increased physical activity. Exercise therapies for 
the management of women diagnosed with PMS/PMDD have not yet been conducted in clinical 
trials.  
 
5.6 HORMONE RECEPTORS IN SKELETAL MUSCLE 
In the present thesis (Paper IV), a significant variation in mRNA and protein levels of the 
steroid hormone receptors ERα and PR were detected in skeletal muscle during three confirmed 
phases of the menstrual cycle in 15 women. The mRNA levels of ERβ were undetectable in all 
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three phases and the mRNA and protein levels of AR were constant and showed no significant 
variation across the menstrual cycle. The relative mRNA and protein levels of steroid hormone 
receptors are displayed in Fig. 24-25.  
There was a significant difference in mRNA levels of ERα between the three phases of the 
menstrual cycle (Fig. 24). The expression of ERα followed a reversed pattern as E2 levels in 
serum. The ERα was significantly higher in the follicular phase, compared to the ovulatory 
phase (p <0.05) and the luteal phase (p <0.001). Furthermore, ERα m RNA levels were 
significantly higher in the ovulatory phase compared to the luteal phase (p >0.001).  The results 
for protein levels of ERα demonstrated a similar pattern as the mRNA levels across the 
menstrual cycle with the highest levels in the follicular phase (Fig. 25). The levels in the 
follicular phase were significantly higher than in the luteal phase (p<0.01). 
A significant overall effect was detected on mRNA levels of PR between the phases (p<0.05) 
(Fig. 24). The PR mRNA levels were significantly lower in the luteal phase, compared to the 
ovulatory phase (p<0.01). There was no significant difference in mRNA levels of PR between 
the follicular and the ovulatory phase. The protein levels of PR displayed a significant overall 
effect across the menstrual cycle (p <0.01), although in a different pattern compared to the 
mRNA levels of PR (Fig. 21). The protein levels of PR were significantly higher in the luteal 
phase of the menstrual cycle, compared to the follicular phase (p <0.01) and the ovulatory phase 
(p <0.01) (Fig. 25).  
 
Fig. 24. Relative mRNA levels of ERα, PR, and AR in the follicular phase (FP, ovulatory phase 
(OP), and luteal phase (LP). The box plots show the median and 25–75%, and the bars show 
the non-outlier range. Levels of significance were set to: *0.05, **0.01, ***0.001.  
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Fig. 25. Protein levels ERα, PR and AR in the FP, OP and LP. For ERα a recombinant protein 
was used to make a standard curve; for PR and AR, cell extract was used to make the 
standard curve. Measured levels of ERα, PR and AR are normalized to microgram of total 
protein. The box plots show the median and 25–75%, and the bars show the non-outlier range. 
Levels of significance were set to: *0.05 and **0.01. 
 
Expression of mRNA of ERα (Lemonie et al., 2003) and expression of mRNA and protein 
levels of both ERα and ERβ (Wiik et al., 2003; 2009) have previously been demonstrated in 
human skeletal muscle tissue. The mRNA expression of ERα was shown to be 180-fold higher 
than the mRNA expression of ERβ (Wiik et al., 2003). The mRNA expression of ERβ was 
undetectable in the present thesis; thus an analysis of protein was not performed. In contrast, 
Wiik et al., (2003) demonstrated protein expression of ERβ in six human adults (three women 
and three men). The differences in results may be explained by the different methods used in the 
studies. In the studies by Wiik et al., (2003; 2009), an immunohistochemistry protocol was used 
to stain ERα and ERβ protein, while in the present thesis, an ELISA assay was used. 
The present thesis is, to the best of our knowledge, the first one to explore ERα in skeletal 
muscle tissue during different phases of the menstrual cycle. The highest levels of mRNA and 
protein of ERα were demonstrated in the early follicular phase when the serum levels of E2 
were at the lowest. Conversely, during the mid-luteal phase, the lowest levels of mRNA and 
protein of ERα were demonstrated when the serum levels of E2 were at their highest. Mertens et 
al., (2001) have studied variation in both ERα and ERβ in different cell types of the 
endometrium (epithelial, grandular, and stromal cells) and showed variation in the levels of the 
estrogen receptors across the menstrual cycle. The highest levels of ERα and ERβ in the 
endometrium were demonstrated during the early proliferative phase, which corresponds with 
the mid- follicular phase in the menstrual cycle. The endometrial cells were shown to gradually 
decline during the secretory (luteal) phase (Mertens et al., 2001). The physical functions of the 
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variation in estrogen receptors in human skeletal muscle are not known. In a cross-sectional 
study, Wiik et al., (2005) have demonstrated a greater mRNA expression in both ERα and ERβ 
in highly endurance-trained male athletes, compared to moderately active males. In some 
studies, estrogen has been suggested to contribute to better trainability of skeletal muscle 
strength (Reis et al., 1995; Sung et al., 2014).  
Progesterone receptors have previously been demonstrated in the skeletal muscle of the pelvic 
floor in postmenopausal women (Copas et al., 2001). In Paper IV, mRNA and protein 
expression of PR were demonstrated in skeletal muscle tissue in the three different phases of the 
menstrual cycle. Progesterone has been suggested to have catabolic properties with regard to 
skeletal muscles (Oosthuyse & Bosch, 2010 review) and may contribute to reduced trainability 
in the luteal phase where serum levels of P-4 are at the highest (Reis et al., 1995; Sung et al., 
2014).  
The serum levels of T (both T and free-T) are generally low in the follicular and luteal phases, 
but a few days prior to the LH surge before ovulation, an approximately 30–45% increase has 
been demonstrated (Sinha-Hikim et al., 1998). This increase in serum T was also demonstrated 
in the present thesis (Paper IV). However, for the AR (at mRNA and protein levels), no 
significant change was recorded across the menstrual cycle (Paper IV). Testosterone is a well-
known anabolic steroid, in the exogenous form in particular (Crewther et al., 2011 review). 
Endogenous testosterone in women is less well studied. No studies have yet been done dealing 
with the effect on skeletal muscle function of the peak in T during the normal menstrual cycle. 
Interestingly, adequate levels of T may compensate for the effect of fatigue in fast-twitch 
muscle fibers and then contribute to better neuromuscular efficiency (Bosco et al., 2000). The 
prevalence of hyperandrogenism and PCOS is common among female Olympic athletes with 
menstrual disturbances (Hagmar & Berglund, 2009). These athletes have been shown to have 
higher levels of T in the bloodstream with an enhanced effect on physical performance 
(Rickenlund et al., 2003). 
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5.7 MUSCULOSKELETAL INJURIES IN RELATION TO HORMONES 
AND PMS 
5.7.1 Musculoskeletal injuries in relation to normal hormonal variation and 
OCs  
Myklebust et al., (1998) reported a higher incidence of sports-related musculoskeletal injuries in 
female elite handball players during the late luteal phase and cycle days 1–2 of the menstrual 
cycle with an occurrence of 14 out of 17 injuries in the proposed phases. Similar findings were 
made by Slauterbeck et al., (2002), who reported the highest incidence during cycle days 1–2.  
Comparably, Möller-Nielsen & Hammar, (1989; 1991) showed, in a prospective study of 86 
female soccer players, a higher injury rate in the luteal phase and at the start of menses in 
women with PMS. Some studies have, however, reported a potential for traumatic sports 
injuries to appear more frequently around the ovulatory phase (cycle days 10–14) (Arendt et al., 
1999; 2002; Wojitys et al., 1998; 2002). Beynnon et al., 2006 showed, in a cross-sectional (case 
control) study on recreational alpine skiers, a significantly higher injury rate in the preovulatory 
phase than in the postovulatory phase, based on serum analyses of progesterone collected a few 
hours post injury in combination with cycle length based on retrospective self-reports. In the 
study by Slauterbeck et al., (2002), the menstrual cycle phases were verified by analyzing levels 
of E2 and P-4 in saliva, in addition to which, self-reports in a later study by Wojtys et al., (2002) 
serum analyses were performed to verify the menstrual cycle phase.  
Only a few prospective studies have divided the data on OC treatment. Möller-Nielsen & 
Hammar, (1989; 1991) showed that women using OCs to have less traumatic injuries compared 
to non-OC users. Ruedl et al., (2009) studied recreational female alpine skiers and found no 
differences in injury rates across the menstrual cycle and no difference between OC users and 
non-OC users.  Similarly, Agel et al., (2006) showed no differences in injury rates (ACL injury 
and ankle sprain) among female athletes (basketball and soccer players) using and not using 
OCs. In two epidemiologic studies on ACL register data, women on OC treatment were less 
likely to have a surgical repair of the ACL compared to matched controls (Gray & Gugala, 
2016; Rahr-Wagner et al., 2014).  
Several studies related to the menstrual cycle in the context of sports medicine suffer from a 
methodological bias with unreliable verification of menstrual cycle phases. Counting days or 
relying on recall in self-reports to estimate cycle phase is feasible and quite usual in these kinds 
of menstrual cycle-related studies. However, these methods give no information about the 
actual levels of sex hormones and conclusions concerning a specific event (injury, muscle 
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strength, etc.) specifically related to a certain phase in the menstrual cycle will be doubtful 
(Vescovi, 2011). It might be inadequate to refer, e.g., to the ovulation phase when not having 
verified the LH surge and mid-luteal rise in P-4. De Jonge et al., (2012) reviewed 12 studies 
related to the menstrual cycle phases and exercise performance and found only five to 
accurately verify the menstrual cycle phases. It is well known that such individual factors as 
increased intensity of physical activity and physical and mental stress have been shown to 
highly influence the characteristics of the normal menstrual cycle (To & Wong, 2000; Russel, et 
al., 1984). In a study on 26 recreationally active women, Schaumberg et al. (2015) illustrated, 
by means of self-reported regular menstrual cycles, the need for adequate and frequent analyses 
of sex hormones during the different phases of the menstrual cycle. They found only 70% of 
their study sample to have an ovulatory menstrual cycle with a sufficient rise in progesterone 
during the mid-luteal phase. The women who did not show a mid-luteal rise in P-4 were 
considered to be anovulatory at that cycle (Schaumberg et al., 2012). Besides, in several 
menstrual cycle-related studies in the sports medicine context, OC users and non-OC users have 
been treated as one group. It might be misleading to compare studies discussing hormonal 
effects during OC ingestion based on endogenous hormone levels.  It is well known that 
synthetic ethinyl estradiol has a higher ER affinity and is more potent than endogenous E2 in 
inducing estrogenic effects in women (Coelingh Bennink, 2004). Traditionally, the phases of 
the normal menstrual cycle (FP, OP, and LP) refer to hormonal variation. In an OC cycle, these 
specific phases do not exist. In monophasic OCs, there are only two different hormonal phases 
(active pill and withdrawal phase). Nevertheless, a serum analysis is needed to verify OC use. 
Serum measures the endogenous sex hormones during OC use, which are supposed to be 
depressed, and the levels of SHBG are expected to be elevated.  
Another confounding factor when studying sex hormone levels in relation to tissue effects, is 
the possible lag between the change in serum hormone levels and the physiological impact on 
performance. For example, in a study by Shultz et al., (2004) using serum analyses on a daily 
basis, a four days delay was demonstrated between the rise in E2 and the effect on knee laxity.  
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5.8 METHODOLOGICAL CONSIDERATIONS 
5.8.1.1 Drop-outs 
 
In menstrual cycle-related studies aimed at exploring physical function, women are often 
followed for a long period of time, in this thesis, at least three months. For that reason, the 
sample size is often limited due to problems concerning compliance with the study protocol and 
treatment. The drop-out rate was high, mainly because women in the OC Starter group found it 
difficulties to detect ovulation with the Ovustrix® after having ended the OC treatment. It is not 
unusual that it may take some time before the return of ovulatory cycles after stopping OC use. 
Nassarella et al., (2008) demonstrated a variation in menstrual cycle length of 31 ± 11 days in 
women who had recently discontinued OC use. In Paper IV, several women had an unpleasant 
experience of the muscle biopsy collection and were unwilling to expose themselves to repeated 
biopsies.  
 
5.8.1.2 OC prescription, PMS ratings and ethics 
Another aspect of an ethical nature is the use of low-dose monophasic OCs and the rating of 
PMS. The women who volunteered to participate in the present thesis study agreed to start OC 
treatment and were carefully examined for exclusion criteria for treatment before the 
prescribing of OCs. The cohort (Papers I–III) of healthy, physically active women showed, in 
general, mild PMS according to ICD-10 and none was diagnosed with PMS/PMDD. 
Unfortunately, in the OC treatment in Papers I–III, the progestagen component in the 
monophasic OCs was not equally distributed over the study group, a variety of six different 
progestagens being used. However, levonorgestrel, a second generation progestagen, was in the 
majority (n = 10).  Additionally, the duration of OC treatment varied widely, which might have 
influenced the outcomes.  
 
5.8.1.3 Verification of cycle phase and OC treatment 
In the present thesis, the menstrual cycle phase and verification of OC use were determined by 
analyzing sex hormones in serum in the morning before breakfast. The blood sampling was 
performed at the same time as the collection of data on postural control (Paper I), muscle 
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strength, hop performance (Paper II), and muscle biopsy (Paper IV) was carried out. To confirm 
the different phases of the menstrual cycle, daily urinary testing, using Ovustix
®
 (LH sticks), 
based on cycle length, was required; together with a serum analysis of hormones.  
 
5.8.1.4 ELISA 
In Paper IV, the expression of hormone receptors in skeletal muscle tissue was analyzed by the 
nonradioactive method, ELISA. The sandwich ELISA quantifies antigens (protein) between two 
layers of antibodies (i.e., capture and detection antibody). This method is considered to be 
highly specific (ELISA encyclopedia, 2017). Immunohistochemistry is another method used to 
study protein expression of hormone receptors and refers to the process of selectively imaging 
antigens by using the principle of antibodies binding specifically to antigens in the skeletal 
muscle tissue. In this method, the antibody-antigen interaction can be visualized and the specific 
site of the protein can be detected.  
 
5.8.1.5 Transmissibility 
The complex interplay between female sex hormones and their relationship to soft tissue-like 
ligament, tendons, skeletal muscles, and musculoskeletal injury remains unclear. As described 
in this thesis, several studies have demonstrated a relationship between the menstrual cycle and 
the OC cycle in relation to physical performance and the risk of sustaining a musculoskeletal 
injury. Most of these studies are, however, small and have important limitations. Since some of 
the studies rely on questionnaires for menstrual cycle days and premenstrual symptoms, the risk 
of a recall bias is notable. Our young, physically active or sedentary women in this thesis are 
probably representative of this population of women, but the sample size might be too small to 
be generalized to a larger group of women. Moreover, the findings might not be applicable to 
female athletes and younger teen-aged females. 
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6 CONCLUSION  
 
• Postural control, measured according to the displacement area, was shown to be altered 
during the active hormone phase (OC phase) in healthy physically active women with 
PMS, compared to women without such symptoms. The displacement area was 
significantly greater in the OC phase than in the withdrawal phase in women with PMS. 
In women without PMS (non-PMS), no differences in postural control between these 
phases were detected.  
• Skeletal muscle strength and hop performance did not vary between a normal menstrual 
cycle and an OC treatment cycle in the same women. Nor did it vary during the 
different phases of the normal menstrual cycle or during the active hormone phase and 
withdrawal phase in OC treatment, as measured in healthy physically active women. 
• OC treatment decreased the ratings of PMS of the somatic type, but it did not affect 
negative mood symptoms in healthy women.  
• Significant variations of mRNA and protein levels of ERα and PR were found in 
skeletal muscle tissue during three hormonally confirmed phases of the normal 
menstrual cycle. The levels of mRNA and protein AR were shown to be constant across 
the menstrual cycle.  
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7 CLINICAL IMPLICATIONS 
 
• The effects of PMS, even mild PMS, influence balance and might even affect complex 
neuromuscular performance and should be accounted for in issues concerning sports 
injuries and the etiology of sports injuries in females.  
• Neuromuscular training has been shown to prevent musculoskeletal injuries in female 
athletes. Hypothetically, it might be even more effective to train complex balance tasks 
in the luteal phase of the menstrual cycle. 
• Since no conclusions regarding different OC formulations and muscle strength can be 
drawn, the choice of OC is still open to the individual female athlete.  
• PMS of variable severity is common, also in healthy, regularly exercising groups of 
women and the ratings of symptoms can be decreased to some extent by the use of 
OCs.      
• The variation in expression of sex hormone receptors in skeletal muscle may have an 
impact on the effects of muscular training and sports injuries in women. 
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8 FUTURE PROSPECTIVES 
 
• There is a great need for continuing research in this area with studies on larger cohorts 
in carefully designed, controlled, and prospectively randomized trials.  
• Studies on the effects of physical performance in relation to the menstrual cycle and 
OCs on well-defined subgroups of women, such as athletes, young women, and women 
with PMS.  
• Studies on specified progestagen components and short-term vs. long-term use of OCs 
to evaluate eventual effects on skeletal muscle strength and neuromuscular 
performance.  
• Clinical trials of individuals (subgroups based on exercise level, PMS, age) aimed at 
constructing tailored rehabilitation programs.  
• Qualitative research-based studies on the individually perceived aspects of periodized 
training and time of injury.  
• Treatment studies evaluating the effect on PMS of using different constructs of exercise 
therapy (e.g., endurance, strength and yoga) on well-defined groups of women 
diagnosed with PMS/PMDD.  
• Further exploration of the physiological effects of the ER, PR, and AR in skeletal 
muscle tissues and the process of adaptation to physical activity.   
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